JP2021531013A - Il2アゴニスト - Google Patents
Il2アゴニスト Download PDFInfo
- Publication number
- JP2021531013A JP2021531013A JP2021503723A JP2021503723A JP2021531013A JP 2021531013 A JP2021531013 A JP 2021531013A JP 2021503723 A JP2021503723 A JP 2021503723A JP 2021503723 A JP2021503723 A JP 2021503723A JP 2021531013 A JP2021531013 A JP 2021531013A
- Authority
- JP
- Japan
- Prior art keywords
- cells
- polypeptide
- amino acid
- antigen
- substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000556 agonist Substances 0.000 title description 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 314
- 108010002350 Interleukin-2 Proteins 0.000 claims abstract description 299
- 102000000588 Interleukin-2 Human genes 0.000 claims abstract description 298
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 225
- 229920001184 polypeptide Polymers 0.000 claims abstract description 203
- 210000004027 cell Anatomy 0.000 claims abstract description 172
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract description 116
- 101001002657 Homo sapiens Interleukin-2 Proteins 0.000 claims abstract description 84
- 102000055277 human IL2 Human genes 0.000 claims abstract description 84
- 238000006467 substitution reaction Methods 0.000 claims abstract description 82
- 239000002157 polynucleotide Substances 0.000 claims abstract description 66
- 102000040430 polynucleotide Human genes 0.000 claims abstract description 66
- 108091033319 polynucleotide Proteins 0.000 claims abstract description 66
- 125000000539 amino acid group Chemical group 0.000 claims abstract description 65
- 238000000034 method Methods 0.000 claims abstract description 60
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 60
- 230000001225 therapeutic effect Effects 0.000 claims abstract description 60
- 210000003289 regulatory T cell Anatomy 0.000 claims abstract description 35
- 108010038453 Interleukin-2 Receptors Proteins 0.000 claims abstract description 33
- 102000010789 Interleukin-2 Receptors Human genes 0.000 claims abstract description 33
- 230000002378 acidificating effect Effects 0.000 claims abstract description 25
- 210000003162 effector t lymphocyte Anatomy 0.000 claims abstract description 20
- 239000000825 pharmaceutical preparation Substances 0.000 claims abstract description 16
- 238000011321 prophylaxis Methods 0.000 claims abstract description 8
- 108091007433 antigens Proteins 0.000 claims description 218
- 102000036639 antigens Human genes 0.000 claims description 218
- 239000000427 antigen Substances 0.000 claims description 214
- 206010028980 Neoplasm Diseases 0.000 claims description 112
- 235000001014 amino acid Nutrition 0.000 claims description 111
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 90
- 201000010099 disease Diseases 0.000 claims description 74
- 201000011510 cancer Diseases 0.000 claims description 63
- 230000028993 immune response Effects 0.000 claims description 54
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 52
- 239000004472 Lysine Substances 0.000 claims description 51
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 42
- 235000013922 glutamic acid Nutrition 0.000 claims description 42
- 239000004220 glutamic acid Substances 0.000 claims description 42
- 230000001939 inductive effect Effects 0.000 claims description 32
- 238000011282 treatment Methods 0.000 claims description 31
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 claims description 30
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims description 30
- 108091006905 Human Serum Albumin Proteins 0.000 claims description 26
- 102000008100 Human Serum Albumin Human genes 0.000 claims description 26
- 108060003951 Immunoglobulin Proteins 0.000 claims description 19
- 102000018358 immunoglobulin Human genes 0.000 claims description 19
- 102000007562 Serum Albumin Human genes 0.000 claims description 18
- 108010071390 Serum Albumin Proteins 0.000 claims description 18
- 208000035475 disorder Diseases 0.000 claims description 12
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 11
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 11
- 208000032839 leukemia Diseases 0.000 claims description 8
- 206010009944 Colon cancer Diseases 0.000 claims description 7
- 206010025323 Lymphomas Diseases 0.000 claims description 7
- 206010060862 Prostate cancer Diseases 0.000 claims description 7
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 7
- 208000029742 colonic neoplasm Diseases 0.000 claims description 7
- 201000001441 melanoma Diseases 0.000 claims description 7
- 206010006187 Breast cancer Diseases 0.000 claims description 6
- 208000026310 Breast neoplasm Diseases 0.000 claims description 6
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 6
- 206010033128 Ovarian cancer Diseases 0.000 claims description 6
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 6
- 208000006265 Renal cell carcinoma Diseases 0.000 claims description 6
- 201000005202 lung cancer Diseases 0.000 claims description 6
- 208000020816 lung neoplasm Diseases 0.000 claims description 6
- 229940127557 pharmaceutical product Drugs 0.000 claims description 6
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 5
- 108090000901 Transferrin Proteins 0.000 claims description 4
- 102000004338 Transferrin Human genes 0.000 claims description 4
- 239000012581 transferrin Substances 0.000 claims description 4
- 206010027406 Mesothelioma Diseases 0.000 claims 2
- 239000000203 mixture Substances 0.000 abstract description 13
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 172
- 210000001744 T-lymphocyte Anatomy 0.000 description 167
- 108090000623 proteins and genes Proteins 0.000 description 149
- 235000018102 proteins Nutrition 0.000 description 143
- 102000004169 proteins and genes Human genes 0.000 description 143
- 239000012634 fragment Substances 0.000 description 81
- 229940024606 amino acid Drugs 0.000 description 73
- 150000001413 amino acids Chemical class 0.000 description 70
- 230000027455 binding Effects 0.000 description 60
- 102000009027 Albumins Human genes 0.000 description 57
- 108010088751 Albumins Proteins 0.000 description 57
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 description 55
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 54
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 53
- 230000035772 mutation Effects 0.000 description 42
- 210000000822 natural killer cell Anatomy 0.000 description 34
- 101800001467 Envelope glycoprotein E2 Proteins 0.000 description 33
- 101800001271 Surface protein Proteins 0.000 description 33
- 210000000612 antigen-presenting cell Anatomy 0.000 description 33
- 239000006228 supernatant Substances 0.000 description 33
- 230000004071 biological effect Effects 0.000 description 32
- 230000000694 effects Effects 0.000 description 32
- 102000004127 Cytokines Human genes 0.000 description 30
- 108090000695 Cytokines Proteins 0.000 description 30
- 230000035755 proliferation Effects 0.000 description 30
- 241000282414 Homo sapiens Species 0.000 description 29
- 241000699670 Mus sp. Species 0.000 description 29
- 108020004999 messenger RNA Proteins 0.000 description 27
- 239000002245 particle Substances 0.000 description 27
- 108020001507 fusion proteins Proteins 0.000 description 26
- 102000037865 fusion proteins Human genes 0.000 description 26
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 description 25
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 description 25
- 150000002632 lipids Chemical class 0.000 description 25
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 description 24
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 description 24
- 230000001965 increasing effect Effects 0.000 description 24
- 239000002479 lipoplex Substances 0.000 description 24
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 24
- 102000015696 Interleukins Human genes 0.000 description 22
- 108010063738 Interleukins Proteins 0.000 description 22
- -1 aromatic amino acids Chemical class 0.000 description 21
- 210000004443 dendritic cell Anatomy 0.000 description 21
- 230000002401 inhibitory effect Effects 0.000 description 21
- 108010074708 B7-H1 Antigen Proteins 0.000 description 20
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 20
- 101100519207 Mus musculus Pdcd1 gene Proteins 0.000 description 20
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 description 20
- 210000004369 blood Anatomy 0.000 description 20
- 239000008280 blood Substances 0.000 description 20
- 230000003993 interaction Effects 0.000 description 20
- 238000000338 in vitro Methods 0.000 description 19
- 230000002829 reductive effect Effects 0.000 description 19
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 17
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 17
- 238000001727 in vivo Methods 0.000 description 17
- 238000012360 testing method Methods 0.000 description 17
- 230000006870 function Effects 0.000 description 16
- 210000000987 immune system Anatomy 0.000 description 16
- 210000004185 liver Anatomy 0.000 description 16
- 210000002966 serum Anatomy 0.000 description 16
- 229960005486 vaccine Drugs 0.000 description 16
- 239000012091 fetal bovine serum Substances 0.000 description 15
- 102000005962 receptors Human genes 0.000 description 15
- 108020003175 receptors Proteins 0.000 description 15
- 210000000952 spleen Anatomy 0.000 description 15
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 15
- 239000002773 nucleotide Substances 0.000 description 14
- 238000002255 vaccination Methods 0.000 description 14
- 241000699666 Mus <mouse, genus> Species 0.000 description 13
- 239000003446 ligand Substances 0.000 description 13
- 210000004698 lymphocyte Anatomy 0.000 description 13
- 230000004048 modification Effects 0.000 description 13
- 238000012986 modification Methods 0.000 description 13
- 238000000684 flow cytometry Methods 0.000 description 12
- 125000003729 nucleotide group Chemical group 0.000 description 12
- 239000000243 solution Substances 0.000 description 12
- 238000013518 transcription Methods 0.000 description 12
- 230000035897 transcription Effects 0.000 description 12
- 230000004913 activation Effects 0.000 description 11
- 238000007792 addition Methods 0.000 description 11
- 239000003795 chemical substances by application Substances 0.000 description 11
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 11
- 238000012217 deletion Methods 0.000 description 11
- 230000037430 deletion Effects 0.000 description 11
- 238000005516 engineering process Methods 0.000 description 11
- 210000002540 macrophage Anatomy 0.000 description 11
- 210000003071 memory t lymphocyte Anatomy 0.000 description 11
- 210000000056 organ Anatomy 0.000 description 11
- 241000894007 species Species 0.000 description 11
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 10
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 10
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 10
- 108010076504 Protein Sorting Signals Proteins 0.000 description 10
- 239000002671 adjuvant Substances 0.000 description 10
- 150000001875 compounds Chemical class 0.000 description 10
- 230000001419 dependent effect Effects 0.000 description 10
- 231100000673 dose–response relationship Toxicity 0.000 description 10
- 230000001404 mediated effect Effects 0.000 description 10
- 230000019491 signal transduction Effects 0.000 description 10
- 230000000638 stimulation Effects 0.000 description 10
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 description 9
- 101710083479 Hepatitis A virus cellular receptor 2 homolog Proteins 0.000 description 9
- 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 description 9
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 9
- 102100020862 Lymphocyte activation gene 3 protein Human genes 0.000 description 9
- 108091054438 MHC class II family Proteins 0.000 description 9
- 102000043131 MHC class II family Human genes 0.000 description 9
- 108700026244 Open Reading Frames Proteins 0.000 description 9
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 9
- 230000002146 bilateral effect Effects 0.000 description 9
- 210000002443 helper t lymphocyte Anatomy 0.000 description 9
- 238000009169 immunotherapy Methods 0.000 description 9
- 238000003780 insertion Methods 0.000 description 9
- 230000037431 insertion Effects 0.000 description 9
- 238000001543 one-way ANOVA Methods 0.000 description 9
- 230000004044 response Effects 0.000 description 9
- 238000007492 two-way ANOVA Methods 0.000 description 9
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 8
- 108020004414 DNA Proteins 0.000 description 8
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 8
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 8
- 108010029485 Protein Isoforms Proteins 0.000 description 8
- 102000001708 Protein Isoforms Human genes 0.000 description 8
- 230000005867 T cell response Effects 0.000 description 8
- 210000000662 T-lymphocyte subset Anatomy 0.000 description 8
- 238000003556 assay Methods 0.000 description 8
- 230000001580 bacterial effect Effects 0.000 description 8
- 125000002091 cationic group Chemical group 0.000 description 8
- 239000003085 diluting agent Substances 0.000 description 8
- 230000002708 enhancing effect Effects 0.000 description 8
- 230000004927 fusion Effects 0.000 description 8
- 239000002502 liposome Substances 0.000 description 8
- 239000002105 nanoparticle Substances 0.000 description 8
- 239000013642 negative control Substances 0.000 description 8
- 230000000069 prophylactic effect Effects 0.000 description 8
- 230000009467 reduction Effects 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- 230000003612 virological effect Effects 0.000 description 8
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 7
- 108020005345 3' Untranslated Regions Proteins 0.000 description 7
- 108020003589 5' Untranslated Regions Proteins 0.000 description 7
- 239000004475 Arginine Substances 0.000 description 7
- 241000282412 Homo Species 0.000 description 7
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 description 7
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 description 7
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 description 7
- 108091008874 T cell receptors Proteins 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 7
- 230000000259 anti-tumor effect Effects 0.000 description 7
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 7
- 210000003719 b-lymphocyte Anatomy 0.000 description 7
- 230000002519 immonomodulatory effect Effects 0.000 description 7
- 239000002609 medium Substances 0.000 description 7
- 239000000546 pharmaceutical excipient Substances 0.000 description 7
- 230000037452 priming Effects 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- 238000012545 processing Methods 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 7
- 238000013519 translation Methods 0.000 description 7
- 210000004881 tumor cell Anatomy 0.000 description 7
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 6
- 102000018651 Epithelial Cell Adhesion Molecule Human genes 0.000 description 6
- 108010066687 Epithelial Cell Adhesion Molecule Proteins 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 101000971533 Homo sapiens Killer cell lectin-like receptor subfamily G member 1 Proteins 0.000 description 6
- 102100021457 Killer cell lectin-like receptor subfamily G member 1 Human genes 0.000 description 6
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 6
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 6
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 6
- 235000004279 alanine Nutrition 0.000 description 6
- 235000003704 aspartic acid Nutrition 0.000 description 6
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 6
- 239000000872 buffer Substances 0.000 description 6
- 210000004899 c-terminal region Anatomy 0.000 description 6
- 230000015556 catabolic process Effects 0.000 description 6
- 238000012054 celltiter-glo Methods 0.000 description 6
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 6
- 238000006731 degradation reaction Methods 0.000 description 6
- 239000012636 effector Substances 0.000 description 6
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 6
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 6
- 230000012010 growth Effects 0.000 description 6
- 208000015181 infectious disease Diseases 0.000 description 6
- 238000001638 lipofection Methods 0.000 description 6
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 6
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 6
- 230000009261 transgenic effect Effects 0.000 description 6
- LDGWQMRUWMSZIU-LQDDAWAPSA-M 2,3-bis[(z)-octadec-9-enoxy]propyl-trimethylazanium;chloride Chemical compound [Cl-].CCCCCCCC\C=C/CCCCCCCCOCC(C[N+](C)(C)C)OCCCCCCCC\C=C/CCCCCCCC LDGWQMRUWMSZIU-LQDDAWAPSA-M 0.000 description 5
- UZOVYGYOLBIAJR-UHFFFAOYSA-N 4-isocyanato-4'-methyldiphenylmethane Chemical compound C1=CC(C)=CC=C1CC1=CC=C(N=C=O)C=C1 UZOVYGYOLBIAJR-UHFFFAOYSA-N 0.000 description 5
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 5
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 5
- 102000037982 Immune checkpoint proteins Human genes 0.000 description 5
- 108091008036 Immune checkpoint proteins Proteins 0.000 description 5
- 125000001176 L-lysyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C([H])([H])C([H])([H])C([H])([H])C(N([H])[H])([H])[H] 0.000 description 5
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 5
- 102000001712 STAT5 Transcription Factor Human genes 0.000 description 5
- 108010029477 STAT5 Transcription Factor Proteins 0.000 description 5
- 230000006044 T cell activation Effects 0.000 description 5
- 238000009171 T-cell vaccination Methods 0.000 description 5
- 108091023045 Untranslated Region Proteins 0.000 description 5
- 241000700605 Viruses Species 0.000 description 5
- 238000009825 accumulation Methods 0.000 description 5
- 239000003937 drug carrier Substances 0.000 description 5
- 229930195712 glutamate Natural products 0.000 description 5
- 239000002955 immunomodulating agent Substances 0.000 description 5
- 230000001926 lymphatic effect Effects 0.000 description 5
- 210000004324 lymphatic system Anatomy 0.000 description 5
- 102000039446 nucleic acids Human genes 0.000 description 5
- 108020004707 nucleic acids Proteins 0.000 description 5
- 150000007523 nucleic acids Chemical class 0.000 description 5
- 244000052769 pathogen Species 0.000 description 5
- 125000002652 ribonucleotide group Chemical group 0.000 description 5
- 210000000130 stem cell Anatomy 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 238000007910 systemic administration Methods 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- KWVJHCQQUFDPLU-YEUCEMRASA-N 2,3-bis[[(z)-octadec-9-enoyl]oxy]propyl-trimethylazanium Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(C[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC KWVJHCQQUFDPLU-YEUCEMRASA-N 0.000 description 4
- 102100038080 B-cell receptor CD22 Human genes 0.000 description 4
- 101100506090 Caenorhabditis elegans hil-2 gene Proteins 0.000 description 4
- 208000035473 Communicable disease Diseases 0.000 description 4
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 description 4
- 101001117317 Homo sapiens Programmed cell death 1 ligand 1 Proteins 0.000 description 4
- 101000611936 Homo sapiens Programmed cell death protein 1 Proteins 0.000 description 4
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 4
- 125000000570 L-alpha-aspartyl group Chemical group [H]OC(=O)C([H])([H])[C@]([H])(N([H])[H])C(*)=O 0.000 description 4
- 125000002059 L-arginyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C([H])([H])C([H])([H])N([H])C(=N[H])N([H])[H] 0.000 description 4
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- 101100179561 Mus musculus Il2ra gene Proteins 0.000 description 4
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 4
- 108091034057 RNA (poly(A)) Proteins 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 229940127174 UCHT1 Drugs 0.000 description 4
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 4
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 4
- 230000000890 antigenic effect Effects 0.000 description 4
- 102220362795 c.256A>G Human genes 0.000 description 4
- 102220427331 c.274A>T Human genes 0.000 description 4
- 238000001516 cell proliferation assay Methods 0.000 description 4
- 230000036755 cellular response Effects 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 238000011260 co-administration Methods 0.000 description 4
- 230000004069 differentiation Effects 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 102000048776 human CD274 Human genes 0.000 description 4
- 102000043321 human CTLA4 Human genes 0.000 description 4
- 102000048362 human PDCD1 Human genes 0.000 description 4
- 210000002865 immune cell Anatomy 0.000 description 4
- 230000001900 immune effect Effects 0.000 description 4
- 230000002163 immunogen Effects 0.000 description 4
- 230000006698 induction Effects 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 230000007935 neutral effect Effects 0.000 description 4
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 4
- 230000026731 phosphorylation Effects 0.000 description 4
- 238000006366 phosphorylation reaction Methods 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 230000003449 preventive effect Effects 0.000 description 4
- 230000002035 prolonged effect Effects 0.000 description 4
- 102200131576 rs121912452 Human genes 0.000 description 4
- 102200158049 rs387906619 Human genes 0.000 description 4
- 230000011664 signaling Effects 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 230000004936 stimulating effect Effects 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 230000009885 systemic effect Effects 0.000 description 4
- 230000008685 targeting Effects 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 4
- 238000011144 upstream manufacturing Methods 0.000 description 4
- 208000023275 Autoimmune disease Diseases 0.000 description 3
- 108700031361 Brachyury Proteins 0.000 description 3
- 102000019034 Chemokines Human genes 0.000 description 3
- 108010012236 Chemokines Proteins 0.000 description 3
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 description 3
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 108010067306 Fibronectins Proteins 0.000 description 3
- 102000016359 Fibronectins Human genes 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 102100031351 Galectin-9 Human genes 0.000 description 3
- 101710121810 Galectin-9 Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 239000004471 Glycine Substances 0.000 description 3
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical class C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 3
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 3
- 101001068133 Homo sapiens Hepatitis A virus cellular receptor 2 Proteins 0.000 description 3
- 101100510618 Homo sapiens LAG3 gene Proteins 0.000 description 3
- 101000610604 Homo sapiens Tumor necrosis factor receptor superfamily member 10B Proteins 0.000 description 3
- 108010074328 Interferon-gamma Proteins 0.000 description 3
- 125000003338 L-glutaminyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C([H])([H])C(=O)N([H])[H] 0.000 description 3
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 3
- 102000008072 Lymphokines Human genes 0.000 description 3
- 108010074338 Lymphokines Proteins 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 239000012980 RPMI-1640 medium Substances 0.000 description 3
- 238000010162 Tukey test Methods 0.000 description 3
- 102100040112 Tumor necrosis factor receptor superfamily member 10B Human genes 0.000 description 3
- 102220606633 Zinc finger protein GLIS1_Q74N_mutation Human genes 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 102220452462 c.242G>T Human genes 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 235000012000 cholesterol Nutrition 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- REZZEXDLIUJMMS-UHFFFAOYSA-M dimethyldioctadecylammonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCCCC[N+](C)(C)CCCCCCCCCCCCCCCCCC REZZEXDLIUJMMS-UHFFFAOYSA-M 0.000 description 3
- 102000049109 human HAVCR2 Human genes 0.000 description 3
- 230000003053 immunization Effects 0.000 description 3
- 229940072221 immunoglobulins Drugs 0.000 description 3
- 229940121354 immunomodulator Drugs 0.000 description 3
- 230000001506 immunosuppresive effect Effects 0.000 description 3
- 230000021633 leukocyte mediated immunity Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 210000001165 lymph node Anatomy 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 229960004641 rituximab Drugs 0.000 description 3
- 102200005671 rs1013940 Human genes 0.000 description 3
- 102220223852 rs1060502978 Human genes 0.000 description 3
- 102220234588 rs1114167484 Human genes 0.000 description 3
- 102220234844 rs1131690927 Human genes 0.000 description 3
- 102200004150 rs147750704 Human genes 0.000 description 3
- 102220082053 rs201520438 Human genes 0.000 description 3
- 102200032604 rs5030773 Human genes 0.000 description 3
- 102220058213 rs730881465 Human genes 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 238000013207 serial dilution Methods 0.000 description 3
- 229940054269 sodium pyruvate Drugs 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 238000010153 Šidák test Methods 0.000 description 3
- OZFAFGSSMRRTDW-UHFFFAOYSA-N (2,4-dichlorophenyl) benzenesulfonate Chemical compound ClC1=CC(Cl)=CC=C1OS(=O)(=O)C1=CC=CC=C1 OZFAFGSSMRRTDW-UHFFFAOYSA-N 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 2
- SNKAWJBJQDLSFF-NVKMUCNASA-N 1,2-dioleoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC SNKAWJBJQDLSFF-NVKMUCNASA-N 0.000 description 2
- LKKMLIBUAXYLOY-UHFFFAOYSA-N 3-Amino-1-methyl-5H-pyrido[4,3-b]indole Chemical compound N1C2=CC=CC=C2C2=C1C=C(N)N=C2C LKKMLIBUAXYLOY-UHFFFAOYSA-N 0.000 description 2
- WEVYNIUIFUYDGI-UHFFFAOYSA-N 3-[6-[4-(trifluoromethoxy)anilino]-4-pyrimidinyl]benzamide Chemical compound NC(=O)C1=CC=CC(C=2N=CN=C(NC=3C=CC(OC(F)(F)F)=CC=3)C=2)=C1 WEVYNIUIFUYDGI-UHFFFAOYSA-N 0.000 description 2
- 101710169336 5'-deoxyadenosine deaminase Proteins 0.000 description 2
- 102100030310 5,6-dihydroxyindole-2-carboxylic acid oxidase Human genes 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 2
- 102000055025 Adenosine deaminases Human genes 0.000 description 2
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 2
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 102100032912 CD44 antigen Human genes 0.000 description 2
- 102100024423 Carbonic anhydrase 9 Human genes 0.000 description 2
- 108010035563 Chloramphenicol O-acetyltransferase Proteins 0.000 description 2
- 102000002029 Claudin Human genes 0.000 description 2
- 108050009302 Claudin Proteins 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- XULFJDKZVHTRLG-JDVCJPALSA-N DOSPA trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F.CCCCCCCC\C=C/CCCCCCCCOCC(C[N+](C)(C)CCNC(=O)C(CCCNCCCN)NCCCN)OCCCCCCCC\C=C/CCCCCCCC XULFJDKZVHTRLG-JDVCJPALSA-N 0.000 description 2
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 101001091269 Escherichia coli Hygromycin-B 4-O-kinase Proteins 0.000 description 2
- 102220565110 Fascin_K43E_mutation Human genes 0.000 description 2
- BCCRXDTUTZHDEU-VKHMYHEASA-N Gly-Ser Chemical compound NCC(=O)N[C@@H](CO)C(O)=O BCCRXDTUTZHDEU-VKHMYHEASA-N 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 108010088652 Histocompatibility Antigens Class I Proteins 0.000 description 2
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 2
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 description 2
- 101001078133 Homo sapiens Integrin alpha-2 Proteins 0.000 description 2
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 description 2
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 2
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 description 2
- 101000851007 Homo sapiens Vascular endothelial growth factor receptor 2 Proteins 0.000 description 2
- 108010031794 IGF Type 1 Receptor Proteins 0.000 description 2
- 102000038455 IGF Type 1 Receptor Human genes 0.000 description 2
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 2
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 2
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 2
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 2
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 2
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 2
- 102100025305 Integrin alpha-2 Human genes 0.000 description 2
- 102000008070 Interferon-gamma Human genes 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 108010066719 Interleukin Receptor Common gamma Subunit Proteins 0.000 description 2
- 102000018682 Interleukin Receptor Common gamma Subunit Human genes 0.000 description 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
- 102100031413 L-dopachrome tautomerase Human genes 0.000 description 2
- 101710093778 L-dopachrome tautomerase Proteins 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- 102100033467 L-selectin Human genes 0.000 description 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 101100407308 Mus musculus Pdcd1lg2 gene Proteins 0.000 description 2
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 108091036407 Polyadenylation Proteins 0.000 description 2
- 108700030875 Programmed Cell Death 1 Ligand 2 Proteins 0.000 description 2
- 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 206010039491 Sarcoma Diseases 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 description 2
- 101710173694 Short transient receptor potential channel 2 Proteins 0.000 description 2
- 108091081024 Start codon Proteins 0.000 description 2
- 101001091268 Streptomyces hygroscopicus Hygromycin-B 7''-O-kinase Proteins 0.000 description 2
- 230000006052 T cell proliferation Effects 0.000 description 2
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
- 239000004473 Threonine Substances 0.000 description 2
- 108010022394 Threonine synthase Proteins 0.000 description 2
- 102000006601 Thymidine Kinase Human genes 0.000 description 2
- 108020004440 Thymidine kinase Proteins 0.000 description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 description 2
- 208000002495 Uterine Neoplasms Diseases 0.000 description 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 201000005188 adrenal gland cancer Diseases 0.000 description 2
- 208000024447 adrenal gland neoplasm Diseases 0.000 description 2
- 230000006229 amino acid addition Effects 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 2
- 230000005975 antitumor immune response Effects 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 235000009582 asparagine Nutrition 0.000 description 2
- 229960001230 asparagine Drugs 0.000 description 2
- 230000006399 behavior Effects 0.000 description 2
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 238000009566 cancer vaccine Methods 0.000 description 2
- 229940022399 cancer vaccine Drugs 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 229940030156 cell vaccine Drugs 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 229960005395 cetuximab Drugs 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 230000009827 complement-dependent cellular cytotoxicity Effects 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000001934 delay Effects 0.000 description 2
- 102000004419 dihydrofolate reductase Human genes 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 230000009881 electrostatic interaction Effects 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 239000012997 ficoll-paque Substances 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 210000004392 genitalia Anatomy 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 208000002672 hepatitis B Diseases 0.000 description 2
- 210000003494 hepatocyte Anatomy 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- 230000028996 humoral immune response Effects 0.000 description 2
- 230000005746 immune checkpoint blockade Effects 0.000 description 2
- 230000007124 immune defense Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 108091008042 inhibitory receptors Proteins 0.000 description 2
- 229960003130 interferon gamma Drugs 0.000 description 2
- 229940047122 interleukins Drugs 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 229960000310 isoleucine Drugs 0.000 description 2
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 2
- JJTUDXZGHPGLLC-UHFFFAOYSA-N lactide Chemical compound CC1OC(=O)C(C)OC1=O JJTUDXZGHPGLLC-UHFFFAOYSA-N 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 238000004020 luminiscence type Methods 0.000 description 2
- 210000002751 lymph Anatomy 0.000 description 2
- 210000001365 lymphatic vessel Anatomy 0.000 description 2
- 210000000207 lymphocyte subset Anatomy 0.000 description 2
- 210000005210 lymphoid organ Anatomy 0.000 description 2
- 238000007726 management method Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 230000007030 peptide scission Effects 0.000 description 2
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 2
- 210000001539 phagocyte Anatomy 0.000 description 2
- 230000004962 physiological condition Effects 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000009696 proliferative response Effects 0.000 description 2
- 239000001294 propane Substances 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 108020001775 protein parts Proteins 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 2
- 238000009097 single-agent therapy Methods 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 210000004989 spleen cell Anatomy 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 231100001274 therapeutic index Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 239000001226 triphosphate Substances 0.000 description 2
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 description 2
- 229940045145 uridine Drugs 0.000 description 2
- 206010046766 uterine cancer Diseases 0.000 description 2
- 239000004474 valine Substances 0.000 description 2
- JSPNNZKWADNWHI-PNANGNLXSA-N (2r)-2-hydroxy-n-[(2s,3r,4e,8e)-3-hydroxy-9-methyl-1-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoctadeca-4,8-dien-2-yl]heptadecanamide Chemical compound CCCCCCCCCCCCCCC[C@@H](O)C(=O)N[C@H]([C@H](O)\C=C\CC\C=C(/C)CCCCCCCCC)CO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O JSPNNZKWADNWHI-PNANGNLXSA-N 0.000 description 1
- SSOORFWOBGFTHL-OTEJMHTDSA-N (4S)-5-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[(2S)-2-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-5-carbamimidamido-1-[[(2S)-5-carbamimidamido-1-[[(1S)-4-carbamimidamido-1-carboxybutyl]amino]-1-oxopentan-2-yl]amino]-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxohexan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-2-oxoethyl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-[[(2S)-2-[[(2S)-2-[[(2S)-2,6-diaminohexanoyl]amino]-3-methylbutanoyl]amino]propanoyl]amino]-5-oxopentanoic acid Chemical compound CC[C@H](C)[C@H](NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H]1CCCN1C(=O)CNC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@@H](N)CCCCN)C(C)C)C(C)C)C(C)C)C(C)C)C(C)C)C(C)C)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O SSOORFWOBGFTHL-OTEJMHTDSA-N 0.000 description 1
- MWRBNPKJOOWZPW-NYVOMTAGSA-N 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine zwitterion Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](COP(O)(=O)OCCN)OC(=O)CCCCCCC\C=C/CCCCCCCC MWRBNPKJOOWZPW-NYVOMTAGSA-N 0.000 description 1
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 1
- KZNQNBZMBZJQJO-UHFFFAOYSA-N 1-(2-azaniumylacetyl)pyrrolidine-2-carboxylate Chemical compound NCC(=O)N1CCCC1C(O)=O KZNQNBZMBZJQJO-UHFFFAOYSA-N 0.000 description 1
- WEYNBWVKOYCCQT-UHFFFAOYSA-N 1-(3-chloro-4-methylphenyl)-3-{2-[({5-[(dimethylamino)methyl]-2-furyl}methyl)thio]ethyl}urea Chemical compound O1C(CN(C)C)=CC=C1CSCCNC(=O)NC1=CC=C(C)C(Cl)=C1 WEYNBWVKOYCCQT-UHFFFAOYSA-N 0.000 description 1
- UZLHBUQJHDTDRD-UHFFFAOYSA-N 2,3-di(tetradecoxy)propyl-(2-hydroxyethyl)-dimethylazanium Chemical compound CCCCCCCCCCCCCCOCC(C[N+](C)(C)CCO)OCCCCCCCCCCCCCC UZLHBUQJHDTDRD-UHFFFAOYSA-N 0.000 description 1
- WALUVDCNGPQPOD-UHFFFAOYSA-M 2,3-di(tetradecoxy)propyl-(2-hydroxyethyl)-dimethylazanium;bromide Chemical compound [Br-].CCCCCCCCCCCCCCOCC(C[N+](C)(C)CCO)OCCCCCCCCCCCCCC WALUVDCNGPQPOD-UHFFFAOYSA-M 0.000 description 1
- CFWRDBDJAOHXSH-SECBINFHSA-N 2-azaniumylethyl [(2r)-2,3-diacetyloxypropyl] phosphate Chemical compound CC(=O)OC[C@@H](OC(C)=O)COP(O)(=O)OCCN CFWRDBDJAOHXSH-SECBINFHSA-N 0.000 description 1
- 101710163881 5,6-dihydroxyindole-2-carboxylic acid oxidase Proteins 0.000 description 1
- ZAYHVCMSTBRABG-UHFFFAOYSA-N 5-Methylcytidine Natural products O=C1N=C(N)C(C)=CN1C1C(O)C(O)C(CO)O1 ZAYHVCMSTBRABG-UHFFFAOYSA-N 0.000 description 1
- ZAYHVCMSTBRABG-JXOAFFINSA-N 5-methylcytidine Chemical compound O=C1N=C(N)C(C)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 ZAYHVCMSTBRABG-JXOAFFINSA-N 0.000 description 1
- VDABVNMGKGUPEY-UHFFFAOYSA-N 6-carboxyfluorescein succinimidyl ester Chemical compound C=1C(O)=CC=C2C=1OC1=CC(O)=CC=C1C2(C1=C2)OC(=O)C1=CC=C2C(=O)ON1C(=O)CCC1=O VDABVNMGKGUPEY-UHFFFAOYSA-N 0.000 description 1
- YXHLJMWYDTXDHS-IRFLANFNSA-N 7-aminoactinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=C(N)C=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 YXHLJMWYDTXDHS-IRFLANFNSA-N 0.000 description 1
- 108700012813 7-aminoactinomycin D Proteins 0.000 description 1
- 102220554188 APC membrane recruitment protein 1_K43A_mutation Human genes 0.000 description 1
- 101710137115 Adenylyl cyclase-associated protein 1 Proteins 0.000 description 1
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 1
- 108010082126 Alanine transaminase Proteins 0.000 description 1
- 239000012099 Alexa Fluor family Substances 0.000 description 1
- 239000004382 Amylase Substances 0.000 description 1
- 102000013142 Amylases Human genes 0.000 description 1
- 108010065511 Amylases Proteins 0.000 description 1
- 102000052587 Anaphase-Promoting Complex-Cyclosome Apc3 Subunit Human genes 0.000 description 1
- 108700004606 Anaphase-Promoting Complex-Cyclosome Apc3 Subunit Proteins 0.000 description 1
- 102100023003 Ankyrin repeat domain-containing protein 30A Human genes 0.000 description 1
- 101100441251 Arabidopsis thaliana CSP2 gene Proteins 0.000 description 1
- 101100222091 Arabidopsis thaliana CSP3 gene Proteins 0.000 description 1
- 101000719121 Arabidopsis thaliana Protein MEI2-like 1 Proteins 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 108091008875 B cell receptors Proteins 0.000 description 1
- 102100035526 B melanoma antigen 1 Human genes 0.000 description 1
- 210000002237 B-cell of pancreatic islet Anatomy 0.000 description 1
- 230000003844 B-cell-activation Effects 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 102000015735 Beta-catenin Human genes 0.000 description 1
- 108060000903 Beta-catenin Proteins 0.000 description 1
- 102100026189 Beta-galactosidase Human genes 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 206010005949 Bone cancer Diseases 0.000 description 1
- 208000018084 Bone neoplasm Diseases 0.000 description 1
- 241000588832 Bordetella pertussis Species 0.000 description 1
- 241001207913 Brentus Species 0.000 description 1
- 101710149863 C-C chemokine receptor type 4 Proteins 0.000 description 1
- 102100036301 C-C chemokine receptor type 7 Human genes 0.000 description 1
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 description 1
- 108700012439 CA9 Proteins 0.000 description 1
- 102100032976 CCR4-NOT transcription complex subunit 6 Human genes 0.000 description 1
- 210000005236 CD8+ effector T cell Anatomy 0.000 description 1
- 210000001239 CD8-positive, alpha-beta cytotoxic T lymphocyte Anatomy 0.000 description 1
- 101150108242 CDC27 gene Proteins 0.000 description 1
- 102100027557 Calcipressin-1 Human genes 0.000 description 1
- 241000282836 Camelus dromedarius Species 0.000 description 1
- 102100025570 Cancer/testis antigen 1 Human genes 0.000 description 1
- 102100039510 Cancer/testis antigen 2 Human genes 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 102100026548 Caspase-8 Human genes 0.000 description 1
- 108090000538 Caspase-8 Proteins 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 1
- 241000606161 Chlamydia Species 0.000 description 1
- 206010008631 Cholera Diseases 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- 102100039518 Claudin-12 Human genes 0.000 description 1
- 101710197000 Claudin-12 Proteins 0.000 description 1
- 102100038449 Claudin-6 Human genes 0.000 description 1
- 108090000229 Claudin-6 Proteins 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 102000000989 Complement System Proteins Human genes 0.000 description 1
- 108010069112 Complement System Proteins Proteins 0.000 description 1
- 229940046168 CpG oligodeoxynucleotide Drugs 0.000 description 1
- MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 description 1
- 102000013701 Cyclin-Dependent Kinase 4 Human genes 0.000 description 1
- 108010025464 Cyclin-Dependent Kinase 4 Proteins 0.000 description 1
- NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 101100216227 Dictyostelium discoideum anapc3 gene Proteins 0.000 description 1
- 108090000204 Dipeptidase 1 Proteins 0.000 description 1
- 208000010772 Dog disease Diseases 0.000 description 1
- 102100025137 Early activation antigen CD69 Human genes 0.000 description 1
- 229940126626 Ektomab Drugs 0.000 description 1
- 208000001976 Endocrine Gland Neoplasms Diseases 0.000 description 1
- 102100039328 Endoplasmin Human genes 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 208000001382 Experimental Melanoma Diseases 0.000 description 1
- 108700004922 F42A Proteins 0.000 description 1
- 229940126611 FBTA05 Drugs 0.000 description 1
- 108010008177 Fd immunoglobulins Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 102100028043 Fibroblast growth factor 3 Human genes 0.000 description 1
- 101710084013 Gene 70 protein Proteins 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 1
- 206010018612 Gonorrhoea Diseases 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
- 102100030595 HLA class II histocompatibility antigen gamma chain Human genes 0.000 description 1
- 102000006354 HLA-DR Antigens Human genes 0.000 description 1
- 108010058597 HLA-DR Antigens Proteins 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 102100028721 Hermansky-Pudlak syndrome 5 protein Human genes 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 101000773083 Homo sapiens 5,6-dihydroxyindole-2-carboxylic acid oxidase Proteins 0.000 description 1
- 101000757191 Homo sapiens Ankyrin repeat domain-containing protein 30A Proteins 0.000 description 1
- 101000874316 Homo sapiens B melanoma antigen 1 Proteins 0.000 description 1
- 101000716065 Homo sapiens C-C chemokine receptor type 7 Proteins 0.000 description 1
- 101000856237 Homo sapiens Cancer/testis antigen 1 Proteins 0.000 description 1
- 101000889345 Homo sapiens Cancer/testis antigen 2 Proteins 0.000 description 1
- 101000721661 Homo sapiens Cellular tumor antigen p53 Proteins 0.000 description 1
- 101000954709 Homo sapiens Doublecortin domain-containing protein 2 Proteins 0.000 description 1
- 101000934374 Homo sapiens Early activation antigen CD69 Proteins 0.000 description 1
- 101000812663 Homo sapiens Endoplasmin Proteins 0.000 description 1
- 101001082627 Homo sapiens HLA class II histocompatibility antigen gamma chain Proteins 0.000 description 1
- 101001009007 Homo sapiens Hemoglobin subunit alpha Proteins 0.000 description 1
- 101000985516 Homo sapiens Hermansky-Pudlak syndrome 5 protein Proteins 0.000 description 1
- 101001078143 Homo sapiens Integrin alpha-IIb Proteins 0.000 description 1
- 101001046677 Homo sapiens Integrin alpha-V Proteins 0.000 description 1
- 101000614481 Homo sapiens Kidney-associated antigen 1 Proteins 0.000 description 1
- 101000878605 Homo sapiens Low affinity immunoglobulin epsilon Fc receptor Proteins 0.000 description 1
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 1
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 description 1
- 101001051093 Homo sapiens Low-density lipoprotein receptor Proteins 0.000 description 1
- 101001134060 Homo sapiens Melanocyte-stimulating hormone receptor Proteins 0.000 description 1
- 101000578784 Homo sapiens Melanoma antigen recognized by T-cells 1 Proteins 0.000 description 1
- 101001028702 Homo sapiens Mitochondrial-derived peptide MOTS-c Proteins 0.000 description 1
- 101000874141 Homo sapiens Probable ATP-dependent RNA helicase DDX43 Proteins 0.000 description 1
- 101000880770 Homo sapiens Protein SSX2 Proteins 0.000 description 1
- 101000679365 Homo sapiens Putative tyrosine-protein phosphatase TPTE Proteins 0.000 description 1
- 101100247605 Homo sapiens RCAN1 gene Proteins 0.000 description 1
- 101001109419 Homo sapiens RNA-binding protein NOB1 Proteins 0.000 description 1
- 101000857677 Homo sapiens Runt-related transcription factor 1 Proteins 0.000 description 1
- 101000633784 Homo sapiens SLAM family member 7 Proteins 0.000 description 1
- 101000821981 Homo sapiens Sarcoma antigen 1 Proteins 0.000 description 1
- 101000665137 Homo sapiens Scm-like with four MBT domains protein 1 Proteins 0.000 description 1
- 101000739178 Homo sapiens Secretoglobin family 3A member 2 Proteins 0.000 description 1
- 101000874179 Homo sapiens Syndecan-1 Proteins 0.000 description 1
- 101000648075 Homo sapiens Trafficking protein particle complex subunit 1 Proteins 0.000 description 1
- 101000904724 Homo sapiens Transmembrane glycoprotein NMB Proteins 0.000 description 1
- 101000610605 Homo sapiens Tumor necrosis factor receptor superfamily member 10A Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 1
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 1
- 102000016844 Immunoglobulin-like domains Human genes 0.000 description 1
- 108050006430 Immunoglobulin-like domains Proteins 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 1
- 108050002021 Integrator complex subunit 2 Proteins 0.000 description 1
- 102100025306 Integrin alpha-IIb Human genes 0.000 description 1
- 102100022337 Integrin alpha-V Human genes 0.000 description 1
- 108010042918 Integrin alpha5beta1 Proteins 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 102000003814 Interleukin-10 Human genes 0.000 description 1
- 108090000174 Interleukin-10 Proteins 0.000 description 1
- 102000013462 Interleukin-12 Human genes 0.000 description 1
- 108010065805 Interleukin-12 Proteins 0.000 description 1
- 102000003816 Interleukin-13 Human genes 0.000 description 1
- 108090000176 Interleukin-13 Proteins 0.000 description 1
- 208000005016 Intestinal Neoplasms Diseases 0.000 description 1
- 206010061252 Intraocular melanoma Diseases 0.000 description 1
- 108010025815 Kanamycin Kinase Proteins 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- 108010092694 L-Selectin Proteins 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 1
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 108091026898 Leader sequence (mRNA) Proteins 0.000 description 1
- 108010028921 Lipopeptides Proteins 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 102100038007 Low affinity immunoglobulin epsilon Fc receptor Human genes 0.000 description 1
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 description 1
- 102100024640 Low-density lipoprotein receptor Human genes 0.000 description 1
- 108091054437 MHC class I family Proteins 0.000 description 1
- 241000282553 Macaca Species 0.000 description 1
- 102100034216 Melanocyte-stimulating hormone receptor Human genes 0.000 description 1
- 102100028389 Melanoma antigen recognized by T-cells 1 Human genes 0.000 description 1
- 102000012750 Membrane Glycoproteins Human genes 0.000 description 1
- 108010090054 Membrane Glycoproteins Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 102100037173 Mitochondrial-derived peptide MOTS-c Human genes 0.000 description 1
- 108010050619 Monokines Proteins 0.000 description 1
- 102000013967 Monokines Human genes 0.000 description 1
- 108010021466 Mutant Proteins Proteins 0.000 description 1
- 102000008300 Mutant Proteins Human genes 0.000 description 1
- 102000003505 Myosin Human genes 0.000 description 1
- 108060008487 Myosin Proteins 0.000 description 1
- QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 description 1
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 description 1
- SUHQNCLNRUAGOO-UHFFFAOYSA-N N-glycoloyl-neuraminic acid Natural products OCC(O)C(O)C(O)C(NC(=O)CO)C(O)CC(=O)C(O)=O SUHQNCLNRUAGOO-UHFFFAOYSA-N 0.000 description 1
- FDJKUWYYUZCUJX-UHFFFAOYSA-N N-glycolyl-beta-neuraminic acid Natural products OCC(O)C(O)C1OC(O)(C(O)=O)CC(O)C1NC(=O)CO FDJKUWYYUZCUJX-UHFFFAOYSA-N 0.000 description 1
- FDJKUWYYUZCUJX-KVNVFURPSA-N N-glycolylneuraminic acid Chemical compound OC[C@H](O)[C@H](O)[C@@H]1O[C@](O)(C(O)=O)C[C@H](O)[C@H]1NC(=O)CO FDJKUWYYUZCUJX-KVNVFURPSA-N 0.000 description 1
- 108010084333 N-palmitoyl-S-(2,3-bis(palmitoyloxy)propyl)cysteinyl-seryl-lysyl-lysyl-lysyl-lysine Proteins 0.000 description 1
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 102000007530 Neurofibromin 1 Human genes 0.000 description 1
- 108010085793 Neurofibromin 1 Proteins 0.000 description 1
- 102220596838 Non-structural maintenance of chromosomes element 1 homolog_R38A_mutation Human genes 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 108060006580 PRAME Proteins 0.000 description 1
- 102000036673 PRAME Human genes 0.000 description 1
- 102100034640 PWWP domain-containing DNA repair factor 3A Human genes 0.000 description 1
- 108050007154 PWWP domain-containing DNA repair factor 3A Proteins 0.000 description 1
- 102220505697 Palmitoyl-protein thioesterase 1_Y45F_mutation Human genes 0.000 description 1
- 241000282577 Pan troglodytes Species 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 208000030852 Parasitic disease Diseases 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- 108010081690 Pertussis Toxin Proteins 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 229940122907 Phosphatase inhibitor Drugs 0.000 description 1
- 208000007913 Pituitary Neoplasms Diseases 0.000 description 1
- 201000005746 Pituitary adenoma Diseases 0.000 description 1
- 206010061538 Pituitary tumour benign Diseases 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 102100035724 Probable ATP-dependent RNA helicase DDX43 Human genes 0.000 description 1
- 102100040678 Programmed cell death protein 1 Human genes 0.000 description 1
- 101710089372 Programmed cell death protein 1 Proteins 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 229930185560 Pseudouridine Natural products 0.000 description 1
- PTJWIQPHWPFNBW-UHFFFAOYSA-N Pseudouridine C Natural products OC1C(O)C(CO)OC1C1=CNC(=O)NC1=O PTJWIQPHWPFNBW-UHFFFAOYSA-N 0.000 description 1
- 206010037423 Pulmonary oedema Diseases 0.000 description 1
- 102100022578 Putative tyrosine-protein phosphatase TPTE Human genes 0.000 description 1
- 102220495631 Putative uncharacterized protein LOC645739_F42A_mutation Human genes 0.000 description 1
- 102000014128 RANK Ligand Human genes 0.000 description 1
- 108010025832 RANK Ligand Proteins 0.000 description 1
- 229940022005 RNA vaccine Drugs 0.000 description 1
- 102100022491 RNA-binding protein NOB1 Human genes 0.000 description 1
- 101150066717 Rara gene Proteins 0.000 description 1
- 108091005682 Receptor kinases Proteins 0.000 description 1
- 101710100969 Receptor tyrosine-protein kinase erbB-3 Proteins 0.000 description 1
- 102100029986 Receptor tyrosine-protein kinase erbB-3 Human genes 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 235000001537 Ribes X gardonianum Nutrition 0.000 description 1
- 235000001535 Ribes X utile Nutrition 0.000 description 1
- 235000016919 Ribes petraeum Nutrition 0.000 description 1
- 244000281247 Ribes rubrum Species 0.000 description 1
- 235000002355 Ribes spicatum Nutrition 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 102100025373 Runt-related transcription factor 1 Human genes 0.000 description 1
- 102100029198 SLAM family member 7 Human genes 0.000 description 1
- 102100021466 Sarcoma antigen 1 Human genes 0.000 description 1
- 102100038689 Scm-like with four MBT domains protein 1 Human genes 0.000 description 1
- 102100037269 Secretoglobin family 3A member 2 Human genes 0.000 description 1
- 206010040070 Septic Shock Diseases 0.000 description 1
- 208000019802 Sexually transmitted disease Diseases 0.000 description 1
- 101710173693 Short transient receptor potential channel 1 Proteins 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 102220506568 Small ubiquitin-related modifier 2_K35E_mutation Human genes 0.000 description 1
- 208000021712 Soft tissue sarcoma Diseases 0.000 description 1
- 102100035748 Squamous cell carcinoma antigen recognized by T-cells 3 Human genes 0.000 description 1
- 101710185775 Squamous cell carcinoma antigen recognized by T-cells 3 Proteins 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 102100035721 Syndecan-1 Human genes 0.000 description 1
- 229940126547 T-cell immunoglobulin mucin-3 Drugs 0.000 description 1
- 108700019889 TEL-AML1 fusion Proteins 0.000 description 1
- 102100033082 TNF receptor-associated factor 3 Human genes 0.000 description 1
- 102220500923 Telomerase reverse transcriptase_K35D_mutation Human genes 0.000 description 1
- 108091036066 Three prime untranslated region Proteins 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 102100025256 Trafficking protein particle complex subunit 1 Human genes 0.000 description 1
- 102000004357 Transferases Human genes 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 102100023935 Transmembrane glycoprotein NMB Human genes 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- LVTKHGUGBGNBPL-UHFFFAOYSA-N Trp-P-1 Chemical compound N1C2=CC=CC=C2C2=C1C(C)=C(N)N=C2C LVTKHGUGBGNBPL-UHFFFAOYSA-N 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102100040113 Tumor necrosis factor receptor superfamily member 10A Human genes 0.000 description 1
- 102100027244 U4/U6.U5 tri-snRNP-associated protein 1 Human genes 0.000 description 1
- 101710155955 U4/U6.U5 tri-snRNP-associated protein 1 Proteins 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 201000005969 Uveal melanoma Diseases 0.000 description 1
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 1
- 102100039037 Vascular endothelial growth factor A Human genes 0.000 description 1
- 102000013127 Vimentin Human genes 0.000 description 1
- 108010065472 Vimentin Proteins 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 241001441550 Zeiformes Species 0.000 description 1
- XYVNHPYNSPGYLI-UUOKFMHZSA-N [(2r,3s,4r,5r)-5-(2-amino-6-oxo-3h-purin-9-yl)-4-hydroxy-2-(phosphonooxymethyl)oxolan-3-yl] dihydrogen phosphate Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H]1O XYVNHPYNSPGYLI-UUOKFMHZSA-N 0.000 description 1
- NYDLOCKCVISJKK-WRBBJXAJSA-N [3-(dimethylamino)-2-[(z)-octadec-9-enoyl]oxypropyl] (z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(CN(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC NYDLOCKCVISJKK-WRBBJXAJSA-N 0.000 description 1
- IEDXPSOJFSVCKU-HOKPPMCLSA-N [4-[[(2S)-5-(carbamoylamino)-2-[[(2S)-2-[6-(2,5-dioxopyrrolidin-1-yl)hexanoylamino]-3-methylbutanoyl]amino]pentanoyl]amino]phenyl]methyl N-[(2S)-1-[[(2S)-1-[[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[[(1S,2R)-1-hydroxy-1-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-methylamino]-3-methyl-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]-N-methylcarbamate Chemical compound CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C)[C@@H](O)c1ccccc1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C(=O)OCc1ccc(NC(=O)[C@H](CCCNC(N)=O)NC(=O)[C@@H](NC(=O)CCCCCN2C(=O)CCC2=O)C(C)C)cc1)C(C)C IEDXPSOJFSVCKU-HOKPPMCLSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 238000000516 activation analysis Methods 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 230000033289 adaptive immune response Effects 0.000 description 1
- 229950009084 adecatumumab Drugs 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N adenyl group Chemical group N1=CN=C2N=CNC2=C1N GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 229950009106 altumomab Drugs 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 229950001537 amatuximab Drugs 0.000 description 1
- 102000006646 aminoglycoside phosphotransferase Human genes 0.000 description 1
- 235000019418 amylase Nutrition 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000002001 anti-metastasis Effects 0.000 description 1
- 230000005809 anti-tumor immunity Effects 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 229950003145 apolizumab Drugs 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 229960003852 atezolizumab Drugs 0.000 description 1
- 230000008267 autocrine signaling Effects 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 206010064097 avian influenza Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- HMFHBZSHGGEWLO-TXICZTDVSA-N beta-D-ribose Chemical group OC[C@H]1O[C@@H](O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-TXICZTDVSA-N 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- WGDUUQDYDIIBKT-UHFFFAOYSA-N beta-Pseudouridine Natural products OC1OC(CN2C=CC(=O)NC2=O)C(O)C1O WGDUUQDYDIIBKT-UHFFFAOYSA-N 0.000 description 1
- 102000006635 beta-lactamase Human genes 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 201000000053 blastoma Diseases 0.000 description 1
- 238000006664 bond formation reaction Methods 0.000 description 1
- 210000004900 c-terminal fragment Anatomy 0.000 description 1
- 102220363900 c.182A>C Human genes 0.000 description 1
- BPKIGYQJPYCAOW-FFJTTWKXSA-I calcium;potassium;disodium;(2s)-2-hydroxypropanoate;dichloride;dihydroxide;hydrate Chemical compound O.[OH-].[OH-].[Na+].[Na+].[Cl-].[Cl-].[K+].[Ca+2].C[C@H](O)C([O-])=O BPKIGYQJPYCAOW-FFJTTWKXSA-I 0.000 description 1
- 238000002619 cancer immunotherapy Methods 0.000 description 1
- 208000035269 cancer or benign tumor Diseases 0.000 description 1
- 229940034605 capromab pendetide Drugs 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 229950000771 carlumab Drugs 0.000 description 1
- 229960000419 catumaxomab Drugs 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 230000005889 cellular cytotoxicity Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 229940106189 ceramide Drugs 0.000 description 1
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 description 1
- 229930183167 cerebroside Natural products 0.000 description 1
- RIZIAUKTHDLMQX-UHFFFAOYSA-N cerebroside D Natural products CCCCCCCCCCCCCCCCC(O)C(=O)NC(C(O)C=CCCC=C(C)CCCCCCCCC)COC1OC(CO)C(O)C(O)C1O RIZIAUKTHDLMQX-UHFFFAOYSA-N 0.000 description 1
- 230000003399 chemotactic effect Effects 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 239000011651 chromium Substances 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000004154 complement system Effects 0.000 description 1
- 238000010668 complexation reaction Methods 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229940028617 conventional vaccine Drugs 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 101150064416 csp1 gene Proteins 0.000 description 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 1
- 208000030381 cutaneous melanoma Diseases 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 210000000172 cytosol Anatomy 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 229960001251 denosumab Drugs 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 229950008962 detumomab Drugs 0.000 description 1
- UMGXUWVIJIQANV-UHFFFAOYSA-M didecyl(dimethyl)azanium;bromide Chemical compound [Br-].CCCCCCCCCC[N+](C)(C)CCCCCCCCCC UMGXUWVIJIQANV-UHFFFAOYSA-M 0.000 description 1
- OGQYPPBGSLZBEG-UHFFFAOYSA-N dimethyl(dioctadecyl)azanium Chemical compound CCCCCCCCCCCCCCCCCC[N+](C)(C)CCCCCCCCCCCCCCCCCC OGQYPPBGSLZBEG-UHFFFAOYSA-N 0.000 description 1
- 206010013023 diphtheria Diseases 0.000 description 1
- 230000009429 distress Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 229960001776 edrecolomab Drugs 0.000 description 1
- 201000008184 embryoma Diseases 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000008393 encapsulating agent Substances 0.000 description 1
- 230000013931 endocrine signaling Effects 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 229950010640 ensituximab Drugs 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000003386 epithelial cell of thymus gland Anatomy 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 102000006815 folate receptor Human genes 0.000 description 1
- 108020005243 folate receptor Proteins 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 229950001109 galiximab Drugs 0.000 description 1
- 229950004896 ganitumab Drugs 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 229960003297 gemtuzumab ozogamicin Drugs 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 208000001786 gonorrhea Diseases 0.000 description 1
- 229940029575 guanosine Drugs 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 230000008348 humoral response Effects 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 230000005965 immune activity Effects 0.000 description 1
- 239000012642 immune effector Substances 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 102000028557 immunoglobulin binding proteins Human genes 0.000 description 1
- 108091009323 immunoglobulin binding proteins Proteins 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 230000004941 influx Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 150000002484 inorganic compounds Chemical class 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 230000002608 insulinlike Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 201000002313 intestinal cancer Diseases 0.000 description 1
- 229950001014 intetumumab Drugs 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 229950010939 iratumumab Drugs 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 229950002884 lexatumumab Drugs 0.000 description 1
- 235000019626 lipase activity Nutrition 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229950000128 lumiliximab Drugs 0.000 description 1
- 108700021021 mRNA Vaccine Proteins 0.000 description 1
- 229940038694 mRNA-based vaccine Drugs 0.000 description 1
- 208000029559 malignant endocrine neoplasm Diseases 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 208000020984 malignant renal pelvis neoplasm Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229950001869 mapatumumab Drugs 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229960005108 mepolizumab Drugs 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 239000013586 microbial product Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000004898 n-terminal fragment Anatomy 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000017066 negative regulation of growth Effects 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 description 1
- 229950010203 nimotuzumab Drugs 0.000 description 1
- 229960003301 nivolumab Drugs 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 201000002575 ocular melanoma Diseases 0.000 description 1
- 229960002450 ofatumumab Drugs 0.000 description 1
- 229950008516 olaratumab Drugs 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 229950007318 ozogamicin Drugs 0.000 description 1
- 101710135378 pH 6 antigen Proteins 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229950010966 patritumab Drugs 0.000 description 1
- 229940067082 pentetate Drugs 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000008823 permeabilization Effects 0.000 description 1
- 229940038309 personalized vaccine Drugs 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 239000008024 pharmaceutical diluent Substances 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229940126620 pintumomab Drugs 0.000 description 1
- 208000021310 pituitary gland adenoma Diseases 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 229920001515 polyalkylene glycol Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 229950009904 pritumumab Drugs 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 235000019419 proteases Nutrition 0.000 description 1
- 230000006337 proteolytic cleavage Effects 0.000 description 1
- PTJWIQPHWPFNBW-GBNDHIKLSA-N pseudouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1C1=CNC(=O)NC1=O PTJWIQPHWPFNBW-GBNDHIKLSA-N 0.000 description 1
- 208000005333 pulmonary edema Diseases 0.000 description 1
- 229950011639 radretumab Drugs 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 201000007444 renal pelvis carcinoma Diseases 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 102200062237 rs121909361 Human genes 0.000 description 1
- 102200041867 rs121918148 Human genes 0.000 description 1
- HNMATTJJEPZZMM-BPKVFSPJSA-N s-[(2r,3s,4s,6s)-6-[[(2r,3s,4s,5r,6r)-5-[(2s,4s,5s)-5-[acetyl(ethyl)amino]-4-methoxyoxan-2-yl]oxy-6-[[(2s,5z,9r,13e)-13-[2-[[4-[(2e)-2-[1-[4-(4-amino-4-oxobutoxy)phenyl]ethylidene]hydrazinyl]-2-methyl-4-oxobutan-2-yl]disulfanyl]ethylidene]-9-hydroxy-12-(m Chemical compound C1[C@H](OC)[C@@H](N(CC)C(C)=O)CO[C@H]1O[C@H]1[C@H](O[C@@H]2C\3=C(NC(=O)OC)C(=O)C[C@@](C/3=C/CSSC(C)(C)CC(=O)N\N=C(/C)C=3C=CC(OCCCC(N)=O)=CC=3)(O)C#C\C=C/C#C2)O[C@H](C)[C@@H](NO[C@@H]2O[C@H](C)[C@@H](SC(=O)C=3C(=C(OC)C(O[C@H]4[C@@H]([C@H](OC)[C@@H](O)[C@H](C)O4)O)=C(I)C=3C)OC)[C@@H](O)C2)[C@@H]1O HNMATTJJEPZZMM-BPKVFSPJSA-N 0.000 description 1
- 235000002020 sage Nutrition 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 210000005212 secondary lymphoid organ Anatomy 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000036303 septic shock Effects 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 229960003323 siltuximab Drugs 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 201000003708 skin melanoma Diseases 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 230000003393 splenic effect Effects 0.000 description 1
- 210000001845 splenic macrophage Anatomy 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 150000003432 sterols Chemical group 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 210000002536 stromal cell Anatomy 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 229950010265 tabalumab Drugs 0.000 description 1
- 101150047061 tag-72 gene Proteins 0.000 description 1
- 229950010259 teprotumumab Drugs 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 229950004742 tigatuzumab Drugs 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 229960005267 tositumomab Drugs 0.000 description 1
- 231100000440 toxicity profile Toxicity 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 229960000575 trastuzumab Drugs 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 102000003390 tumor necrosis factor Human genes 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 239000012646 vaccine adjuvant Substances 0.000 description 1
- 229940124931 vaccine adjuvant Drugs 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 210000005048 vimentin Anatomy 0.000 description 1
- 210000000605 viral structure Anatomy 0.000 description 1
- 229950009002 zanolimumab Drugs 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001136—Cytokines
- A61K39/00114—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
- A61K2039/55527—Interleukins
- A61K2039/55533—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
Abstract
Description
−35位、
−43位、
−61位、
−62位、
−35位および43位、
−35位および61位、
−35位および62位、
−43位および61位、
−43位および62位、
−61位および62位、
−35位、43位および61位、
−35位、43位および62位、
−35位、61位および62位、
−43位、61位および62位、または
−35位、43位、61位および62位。
−35位、
−43位、
−61位、
−62位、
−35位および43位、
−35位および61位、
−35位および62位、
−43位および61位、
−43位および62位、
−61位および62位、
−35位、43位および61位、
−35位、43位および62位、
−35位、61位および62位、
−43位、61位および62位、または
−35位、43位、61位および62位。
(i)74N、80F、81D、85V、86V、89V、92F;
(ii)74H、80F、81D、85V、86V、92F;
(iii)74S、80F、81D、85V、86V、92F;
(iv)74N、80F、81D、85V、86V、92F;
(v)80F、81D、85V、86V、92F;
(vi)80F、81D、85V、86V、89V、92F、93I;
(vii)18R、22E、80F、81D、85V、86V、89V、92F、93I、126T;
(viii)18R、22E、74S、80F、81T、85V、86V、89V、92F、93I、126T。
−35位、
−43位、
−61位、
−62位、
−35位および43位、
−35位および61位、
−35位および62位、
−43位および61位、
−43位および62位、
−61位および62位、
−35位、43位および61位、
−35位、43位および62位、
−35位、61位および62位、
−43位、61位および62位、または
−35位、43位、61位および62位。
(i)74N、80F、81D、85V、86V、89V、92F;
(ii)74H、80F、81D、85V、86V、92F;
(iii)74S、80F、81D、85V、86V、92F;
(iv)74N、80F、81D、85V、86V、92F;
(v)80F、81D、85V、86V、92F;
(vi)80F、81D、85V、86V、89V、92F、93I;
(vii)18R、22E、80F、81D、85V、86V、89V、92F、93I、126T;
(viii)18R、22E、74S、80F、81T、85V、86V、89V、92F、93I、126T。
a.本明細書に記載のIL2変異体ポリペプチド、本明細書に記載のIL2変異体ポリペプチドをコードするポリヌクレオチド、本明細書に記載のIL2変異体ポリペプチドをコードするポリヌクレオチドを含む宿主細胞、または本明細書に記載の医薬組成物;および
b.対象において抗原に対する免疫応答を誘導するためのエピトープを含むペプチドまたはタンパク質、または前記ペプチドもしくはタンパク質をコードするポリヌクレオチド。
a.本明細書に記載のIL2変異体ポリペプチドをコードするRNA;および
b.対象において抗原に対する免疫応答を誘導するためのエピトープを含むペプチドまたはタンパク質をコードするRNA。
a.本明細書に記載のIL2変異体ポリペプチド、本明細書に記載のIL2変異体ポリペプチドをコードするポリヌクレオチド、本明細書に記載のIL2変異体ポリペプチドをコードするポリヌクレオチドを含む宿主細胞、または本明細書に記載の医薬組成物;および
b.対象において腫瘍関連抗原に対する免疫応答を誘導するためのエピトープを含むペプチドまたはタンパク質、または前記ペプチドもしくはタンパク質をコードするポリヌクレオチド。
a.本明細書に記載のIL2変異体ポリペプチドをコードするRNA;および
b.対象において腫瘍関連抗原に対する免疫応答を誘導するためのエピトープを含むペプチドまたはタンパク質をコードするRNA。
a.本明細書に記載のIL2変異体ポリペプチド、本明細書に記載のIL2変異体ポリペプチドをコードするポリヌクレオチド、本明細書に記載のIL2変異体ポリペプチドをコードするポリヌクレオチドを含む宿主細胞、または本明細書の記載の医薬組成物。
b.対象において抗原に対する免疫応答を誘導するためのエピトープを含むペプチドまたはタンパク質、または前記ペプチドもしくはタンパク質をコードするポリヌクレオチド。
a.本明細書に記載のIL2変異体ポリペプチドをコードするRNA;および
b.対象において抗原に対する免疫応答を誘導するためのエピトープを含むペプチドまたはタンパク質をコードするRNA。
a.前記ポリペプチド、前記ポリヌクレオチド、前記宿主細胞、または前記医薬組成物;および
b.対象において抗原に対する免疫応答を誘導するためのエピトープを含むペプチドまたはタンパク質、または前記ペプチドもしくはタンパク質をコードするポリヌクレオチド。
a.本明細書に記載のIL2変異体ポリペプチドをコードするRNA;および
b.対象において抗原に対する免疫応答を誘導するためのエピトープを含むペプチドまたはタンパク質をコードするRNA。
a.前記ポリペプチド、前記ポリヌクレオチド、前記宿主細胞、または前記医薬組成物;および
b.対象において腫瘍関連抗原に対する免疫応答を誘導するためのエピトープを含むペプチドまたはタンパク質、または前記ペプチドもしくはタンパク質をコードするポリヌクレオチド。
a.本明細書に記載のIL2変異体ポリペプチドをコードするRNA;および
b.対象において腫瘍関連抗原に対する免疫応答を誘導するためのエピトープを含むペプチドまたはタンパク質をコードするRNA。
定義
グリシン、アラニン;
バリン、イソロイシン、ロイシン;
アスパラギン酸、グルタミン酸;
アスパラギン、グルタミン;
セリン、トレオニン;
リジン、アルギニン;および
フェニルアラニン、チロシン。
(i)74N、80F、81D、85V、86V、89V、92F;
(ii)74H、80F、81D、85V、86V、92F;
(iii)74S、80F、81D、85V、86V、92F;
(iv)74N、80F、81D、85V、86V、92F;
(v)80F、81D、85V、86V、92F;
(vi)80F、81D、85V、86V、89V、92F、93I;
(vii)18R、22E、80F、81D、85V、86V、89V、92F、93I、126T;
(viii)18R、22E、74S、80F、81T、85V、86V、89V、92F、93I、126T。
1)IL2Rβγにおけるアゴニスト作用。この特性は、IL2に依存する細胞株を用いたインビトロ増殖アッセイで直接評価することができる。
構築物の設計およびmRNAの作製
サイトカインをコードするmRNAのインビトロ転写は、pST1−T7−AGA−dEarI−hAg−MCS−FI−A30LA70プラスミド骨格および誘導体DNA構築物に基づいた。これらのプラスミド構築物は、5'UTR(非翻訳領域、ホモサピエンス(homo sapiens)ヘモグロビンサブユニットα1(hAg)の5'−UTRの誘導体)、3'FIエレメント(Fはスプリットのアミノ末端エンハンサの136ヌクレオチド長の3´−UTR断片であるmRNAであり、Iはミトコンドリアにコードされた12S RNAの142ヌクレオチド長の断片であり、両方ともホモサピエンスにおいて同定されている;国際公開第2017/060314号)、および100ヌクレオチドのポリ(A)尾部と、70ヌクレオチドの後にリンカーを含む。サイトカインおよび血清アルブミン(hAlb)をコードする配列はホモサピエンスに由来し、以下で説明するmutIL2変異体の意図した変異を除いて、結果として生じるアミノ酸配列の変化は導入しなかった(hIL2:NP_000577.2;NCBIタンパク質リソース;https://www.ncbi.nlm.nih.gov/protein/)。hAlbを、IL2変異体のN末端またはC末端のいずれかに、インビトロおよびインビボで同様に有効である両方の配向で付加した(データは示していない)。コードされるタンパク質は、それぞれのタンパク質の天然シグナルペプチドであるN末端シグナルペプチド(SP)を備える。融合タンパク質の場合、N末端部分のSPのみを維持し、さらなる部分については成熟部分(SPのないタンパク質)のみをコードした。終止コドンは、ほとんどのC末端部分についてのみ導入した。サイトカインおよびhAlb融合構築物の異なるタンパク質部分は、グリシンおよびセリン残基をコードする30ヌクレオチド長のリンカー配列によって分離した。hIL2配列の変異を導入して、CD25結合を改変し(「mutCD25」変異と称し、それぞれの構築物をhIL2_Axと命名し、xは以下で定義される)、およびIL2Rβγへの結合を改変した(「mutβγ」変異と称し、それぞれの構築物を追加の「s」で表示し、例えばhIL2sまたはhIL2_A4sと表示する)。hIL2_A1の場合、成熟ドメインの4つのアミノ酸残基置換を導入し、38位のアルギニンをアラニンに変更し(R38A)、42位のフェニルアラニンをアラニンに変更し(F42A)、45位のチロシンをアラニンに変更し(Y45A)、62位のグルタミン酸をアラニンに変更した(E62A)(Carmenate,T.et al.J.Immunol.190,6230−6238(2013))。hIL2_A2については、成熟ドメインのアミノ酸残基置換は、K35A、K43AおよびE61Aである。hIL2_A3については、置換K35E、K43EおよびE61Kを導入し、hIL2_A4にはK43EおよびE61K、hIL2_A5にはE61K、およびhIL2_A6にはE62K変異を導入した。hIL2 mutβγ変異体の生成のために、それぞれのhIL2変異体の成熟ドメインのアミノ酸残基を、L80F、R81D、L85V、I86VおよびI92Fの方法で置換した(Levin,A.M.et al.Nature 484,529−533(2012))。mRNAは、通常のヌクレオシドであるウリジンを1−メチルプソイドウリジンに置き換えて、Kreiter et al.(Kreiter,S.et al.Cancer Immunol.Immunother.56,1577−87(2007))によって記述されているようにインビトロ転写によって生成した。得られたmRNAはキャップ1構造を備えており、二本鎖(dsRNA)分子を枯渇させた。精製したmRNAをH2Oで溶出し、さらに使用するまで−80°Cで保存した。記載されているすべてのmRNA構築物のインビトロ転写は、BioNTech RNA Pharmaceuticals GmbHで実施された。その後の実験で使用したすべての構築物のリストを表1に示す。
RNAにコードされたIL2変異体のインビトロ発現およびIL2Rβγ結合
生成されたmRNAのインビトロ発現を、HEK293T/17細胞へのmRNAのリポフェクションと、それに続くIL2 mutCD25変異体によるIL2Rβγ発現レポータ細胞のCD25非依存性活性化の分析によって分析した(図1)。リポフェクションの1日前に、1.2x106個のHEK293T/17細胞を、6ウェルプレート中の3mL DMEM(Life Technologies GmbH、カタログ番号31966−021)+10%ウシ胎仔血清(FBS、Biochrom GmbH、カタログ番号S0115)に播種した。リポフェクションのために、3μgのmRNAを無菌のRNアーゼ不含条件下で、Lipofectamine MessengerMax(Thermo Fisher Scientific、カタログ番号LMRNA015)1μLあたり400ngのmRNAを使用して製剤化し、10cm2の培養皿ごとに約80%の集密度でHEK293T/17細胞に適用した。20時間の発現後に、上清を無菌条件下で収集し、さらに使用するまで−20℃で保存した。IL2 mutCD25変異体のIL2Rβγ依存性生物活性を、中親和性IL2受容体(IL2Rβγ)を発現するTF−1_IL2Rβγ細胞の特異的増殖応答を測定することによって評価した。この細胞株は、IL2R共通γ鎖を天然に発現するヒト赤白血病細胞株であるTF−1細胞株(ATCC CRL−2003)から、Farner,N.L.et al.Blood 86,4568−4578(1995)と同様に、ヒトIL2Rβ鎖の配列をコードするレトロウイルスベクター(遺伝子ID:3560)による形質導入によって生成した。手短に言うと、TF−1_IL2Rβγ細胞をD−PBSで2回洗浄し、10%ウシ胎仔血清(FBS;Biochrom GmbH、カタログ番号S0115)および1mMピルビン酸ナトリウム(Life Technologies GmbH、カタログ番号11360070)を添加したRPMI 1640(Life Technologies GmbH、カタログ番号61870010)に再懸濁した。合計5,000細胞/ウェルを白色96ウェル平底プレート(Fisher Scientific GmbH、カタログ番号10072151)に播種し、IL2変異体含有上清の4倍段階希釈液と共にインキュベートした。3日間の培養後、CellTiter−Glo(登録商標)2.0 Assay(Promega、カタログ番号G9242)を使用してATP量で生細胞を定量することによって増殖を測定した。発光をTecan Infinite(登録商標)F200 PROリーダ(Tecan Deutschland GmbH)で記録し、GraphPad Prismバージョン6.04(GraphPad Software,Inc.)で用量反応曲線をプロットした。
RNAにコードされたIL2 mutCD25変異体の組換えCD25(IL2Rα)への結合
mRNAにコードされたIL2 mutCD25変異体の組換えCD25への結合をELISAによって分析した(図2)。ここで、1μg/mLの組換えヒトまたはマウスCD25(C−Fc、Novoproteinカタログ番号CJ78、CK32)を、100μLのDPBS中で高タンパク質結合96ウェルプレート(Nunc MaxiSorp(商標)、Thermo Fisher Scientific、カタログ番号439454)に被覆した。HEK−293−T−17のリポフェクションによって生成されたIL2変異体含有上清(実施例2に記載)を、被覆したCD25に適用し、結合したタンパク質をHRP結合抗ヒト血清アルブミン抗体(Abcam、カタログ番号ab8941)によって検出した。一般的なELISA試薬と手順を、DuoSet ELISA Ancillary Reagent Kit 2(R&D Systems、カタログ番号DY008)のプロトコルに従って適用した。
RNAにコードされたIL2 mutCD25変異体のCD25依存性CTLL−2増殖に対する生物活性。
IL2 mutCD25変異体の生物学的活性を、CD25を高発現するマウスCTLL−2細胞(マウスC57BL/6 T細胞株、ATCC TIB−214)のサイトカイン依存性増殖を分析することによって評価した(図3)。手短に言うと、CTLL−2細胞を回収し、DPBSで2回洗浄して残留IL2を除去し、10%ウシ胎仔血清(FBS;Biochrom GmbH、カタログ番号S0115)および1mMピルビン酸ナトリウム(Life Technologies GmbH、カタログ番号11360070)を添加したRPMI 1640(Life Technologies GmbH、カタログ番号61870010)に再懸濁した。合計5,000細胞/ウェルを白色96ウェル平底プレート(Fisher Scientific GmbH、カタログ番号10072151)に播種し、4倍に段階希釈したIL2変異体含有上清(実施例2に記載)と共にインキュベートした。3日間の培養後、CellTiter−Glo(登録商標)2.0 Assay(Promega、カタログ番号G9242)を使用してATP量で生細胞を定量することによって増殖を測定した。発光をTecan Infinite(登録商標)F200 PROリーダ(Tecan Deutschland GmbH)で記録し、GraphPad Prismバージョン6.04(GraphPad Software,Inc.)で用量反応曲線をプロットした。
RNAにコードされたIL2変異体のヒトPBMC増殖に対する生物活性。
末梢血単核細胞(PBMC)の増殖を測定するために、PBMCを最適以下の濃度の抗CD3抗体(クローンUCHT1)およびIL2変異体をコードするmRNAを含むHEK293T/17のリポフェクションに由来する上清または対照上清と共にインキュベートした。手短に言うと、PBMCを、Ficoll−Paque(VWR International、カタログ番号17−1440−03)密度勾配分離によって健常ドナーのバフィコートから得た。1.6μMのカルボキシフルオレセインスクシンイミジルエステル(CFSE;Thermo Fisher、カタログ番号C34564)を使用してPBMCを標識した。ウェルあたり75,000個のCFSE標識PBMCを、96ウェル丸底プレート(Costar、カタログ番号734−1797)中の5%血漿由来ヒト血清(PHS;One Lambda lnc.、カタログ番号A25761)を添加したlscoveの改変ダルベッコ培地(IMDM;Life Technologies GmbH、カタログ番号12440−053)に播種し、各ドナーについて事前に決定された最適以下の濃度の抗CD3抗体(クローンUCHT1;R&D Systems、カタログ番号MAB100;最終濃度0.03〜0.09μg/mL)と共にインキュベートした。並行して、IL2変異体含有上清の4倍段階希釈液(実施例2を参照)を、5%PHSを添加したIMDMで生成した。播種した細胞をIL2変異体上清と1:1で混合し(播種した細胞の培地の容量を参照)、37℃、5%CO2で4日間刺激した。PBMCを回収し、フローサイトメトリで分析した。細胞を、FACS緩衝液(5%FBSおよび5mM EDTAを含むD−PBS)ですべて1:100に希釈した以下の試薬で染色した:抗ヒトCD4−PE(TONBO Bioscience、カタログ番号50−0049)、抗ヒトCD8−PE(TONBO Bioscience、カタログ番号50−0088)、抗ヒトCD56−APC(eBioscience、カタログ番号17−0567−42)および7−AAD(Beckman Coulter、カタログ番号A07704)。フローサイトメトリ分析を、増殖読み出しとしてCFSE希釈を用いてBD FACSCanto(商標)IIフローサイトメータ(Becton Dickinson)で実施した。取得した増殖データを、FlowJo 10.4ソフトウェアを使用して分析し、エクスポートした拡張指数値を使用してGraphPad Prismバージョン6.04(GraphPad Software,Inc.)で用量反応曲線をプロットした。
中親和性IL2受容体(IL2Rβγ)対高親和性IL2受容体(IL2Rαβγ)を発現するIL2依存性レポータ細胞株における様々なIL2変異体の相対的生物活性の比較。
様々なIL2変異体の生物学的活性の決定因子としてのIL2Rα鎖(CD25)の役割を分析するために、高親和性IL2受容体(IL2Rαβγ)を発現するマウスT細胞株CTLL−2の特異的増殖応答を、IL2Rβ鎖も発現するように形質導入された、IL2R共通γ鎖を天然に発現するヒト赤白血病細胞株である、中親和性IL2受容体(IL2Rβγ)を発現するTF−1_IL2Rβγ細胞と比較した(実施例2を参照)。手短に言うと、CTLL−2およびTF−1_IL2Rβγ細胞をD−PBSで2回洗浄し、10%ウシ胎仔血清(FBS;Biochrom GmbH、カタログ番号S0115)および1mMピルビン酸ナトリウム(Life Technologies GmbH、カタログ番号11360070)を添加したRPMI 1640(Life Technologies GmbH、カタログ番号61870010)に再懸濁した。合計5,000細胞/ウェルを白色96ウェル平底プレート(Fisher Scientific GmbH、カタログ番号10072151)に播種し、IL2変異体含有上清の5つの4倍段階希釈液(実施例2に記載)と共にインキュベートした。3日間の培養後、CellTiter−Glo(登録商標)2.0 Assay(Promega、カタログ番号G9242)を使用してATP量で生細胞を定量することによって増殖を測定した。発光をTecan Infinite(登録商標)F200 PROリーダ(Tecan Deutschland GmbH)で記録し、GraphPad Prismバージョン6.04(GraphPad Software,Inc.)で用量反応曲線をプロットし、EC50値を計算した。
STAT5リン酸化を読み出しとして使用した、ヒトPBMCにおける様々なT細胞サブセットに対するhAlb−hIL2変異体の活性の比較。
CD25が欠損しているかまたは発現される様々なT細胞サブセットに対するhAlb−hIL2変異体の活性を評価するために、ヒトPBMC全体をhAlb−hIL2変異体で刺激し、様々なサイトカイン希釈でSTAT5リン酸化をアッセイした。手短に言うと、PBMCを、Ficoll−Paque(VWR International、カタログ番号17−1440−03)密度勾配分離によって健常ドナーのバフィコートから得た。PBMCをD−PBS(Life Technologies GmbH、カタログ番号14190250)で2回洗浄し、室温で300×g、5分間の遠心分離によって収集した。PBMCを、10%ウシ胎仔血清(FBS;Biochrom GmbH、カタログ番号S0115)を添加したlscoveの改変ダルベッコ培地(IMDM;Life Technologies GmbH、カタログ番号12440−053)に再懸濁し、37°Cおよび5%CO2で1時間静置した。次に、96ウェルV底プレート(Greiner Bio−One GmbH、カタログ番号651101)のウェルあたり100,000個のPBMCを、10%FBSおよび2倍のPhosSTOP(商標)ホスファターゼ阻害剤(Sigma−Aldrich、カタログ番号04906845001)を添加したIMDMに播種した。並行して、hAlb−hIL2変異体含有上清の5つの4倍段階希釈液(実施例2に記載)を、10%FBSを添加したIMDMで生成した。播種した細胞をhAlb−hIL2変異体上清と1:1で混合し(播種した細胞の培地の容量を参照)、37℃および5%CO2で10分間刺激した。次に、1:1,000の固定可能な生存率色素eFluor(商標)780を添加し、細胞を37°Cおよび5%CO2でさらに5分間刺激した。ホルムアルデヒド(Carl Roth GmbH+Co.KG、カタログ番号P087.4)を2%まで添加して細胞を固定し、氷上で10分間インキュベートした。固定したPBMCを氷冷D−PBSで洗浄し、100%氷冷メタノールを用いて氷上で30分間透過処理した。透過処理したPBMCを1倍の透過処理緩衝液(eBioscience Inc.、カタログ番号00−8333−56)で2回洗浄し、その後1倍の透過処理緩衝液中で遮光して2〜8°Cで30分間、1:5のAlexa Fluor(登録商標)488抗Stat5(pY694)(Becton Dickinson GmbH、カタログ番号612598)、1:25のPerCP−C(商標)5.5マウス抗ヒトCD25(Becton Dickinson GmbH、カタログ番号560503)、1:25のAPCラット抗FOXP3(eBioscience Inc.、17−4776−41)、1:25のBV421マウス抗ヒトCD4(Becton Dickinson GmbH、カタログ番号565997)、および1:25のBV510マウス抗ヒトCD8(Becton Dickinson GmbH、カタログ番号563256)で染色した。染色したPBMCを氷冷した1倍透過処理緩衝液で2回洗浄し、最後に2%FBSおよび2mM EDTA(Sigma−Aldrich、カタログ番号03690−100ML)を添加したD−PBSに再懸濁した。フローサイトメトリ分析をBD FACSCanto(商標)IIフローサイトメータ(Becton Dickinson GmbH)で実施し、取得したデータをFlowJoソフトウェアバージョン10.3を使用して分析した。用量反応曲線およびEC50値をGraphPad Prismバージョン6.04(GraphPad Software,Inc.)で計算した。
インビボでのT細胞ワクチン接種に対するIL2 mutCD25変異体の作用
その後、IL2 mutCD25変異体hIL2_A4およびhIL2_A6がインビボでRNAワクチンによって誘導されるT細胞応答に及ぼす影響を特徴付けた。Kranz,L.M.et al.Nature 534,396−401(2016)に記載されているように、BALB/cマウス(群あたりn=5)に、CD8+T細胞抗原gp70(SPSYAYHQF)をコードする20μgのRNA−LPXを静脈内ワクチン接種した。Gp70は、例えば結腸癌細胞株CT26に認められる腫瘍抗原である。gp70標的ワクチンの抗腫瘍効果は、誘導されるgp70特異的T細胞の数が増えるにつれて増加する(Kranz,L.M.et al.Nature 534,396−401(2016)および未発表)。ワクチン接種の3日後、hAlb(陰性対照)またはLNPとして製剤化された漸増用量のhAlb−hIL2、hAlb−hIL2_A4、hAlb−hIL2_A6 RNAを、図7に示すように静脈内投与した。7日目に、フローサイトメトリ(BD FACSCelesta)による血液リンパ球サブセットおよびgp70特異的T細胞(MHCテトラマー、MBL)の免疫表現型検査を含む分析を実施した(Kranz,L.M.et al.Nature 534,396−401(2016)に記載されている染色)。
mutβγ変異の追加によるIL2 mutCD25変異体の有効性の改善
変異体hAlb−hIL2_A4およびhAlb−hIL2_A6は、CD8+T細胞対Tregの比率を大幅に増加させたが、抗原特異的T細胞の強力な増殖には、活性化T細胞上の高親和性IL2Rαβγへの結合が減少するため、hAlb−hIL2と比較してはるかに高い用量が必要であった。したがって、インビボでのhAlb−hIL2_A4およびhAlb−hIL2_A6の効力が、インビトロですべてのIL2Rβγ陽性細胞への結合を改善することが示されたmutβγ変異の導入によってさらに改善できるかどうかを試験した(実施例5〜7;Levin,A.M.et al.Nature 484,529−533(2012))。実施例8と同様に、BALB/cマウス(群あたりn=5)に20μgのgp70 RNA−LPXを静脈内ワクチン接種し、3日後にサイトカインRNA−LNPを注射した(図7A)。この実験では、mutβγ変異による改善が十分にカバーされることを確認し、治療用量の下限を試験するために、サイトカインRNA−LNP用量を大幅に低減した。ワクチン接種の7日後、gp70特異的T細胞、NK細胞、およびCD25 FoxP3陽性Tregを分析した(図8)。
mutCD25とmutβγ変異の両方の変異を含むhAlb−hIL2変異体は、mutβγ変異を含むIL2および野生型hAlb−hIL2と比較して優れている
実施例9では、mutCD25変異体へのmutβγ変異の導入が、Tregの頻度を増加させることなく抗原特異的T細胞を刺激する効力を高めることを示した。次に、mutCD25とmutβγの両方の変異を含むIL2変異体が、mutβγを含むIL2変異体(hAlb−hIL2s)よりも優れているかどうかを試験したいと考えた。BALB/cマウス(群あたりn=5)に、0日目と7日目に20μgのgp70 RNA−LPXを、3日目と10日目にサイトカインRNA−LNP(図に示されている用量)を静脈内ワクチン接種した。フローサイトメトリによる血液リンパ球の分析(実施例8を参照)を7日目と14日目に実施した(図9A)。抗原特異的T細胞数は、hAlb対照と比較してすべてのIL2変異体でブーストされた(図9B)。重要な点として、hAlb−hIL2およびより低い程度でhAlb−hIL2sはTregを拡大したが、hAlb−hIL2_A4sおよびhAlb−hIL2_A6sで処置した群では、Treg数は増加しなかった(図9C)。hAlb−hIL2_A4sおよびhAlb−hIL2_A6sによるTreg増殖の欠如は、hAlb−hIL2およびhAlb−hIL2s変異体の効果を上回る、2回目の処置後の抗原特異的T細胞の強力なブーストを説明し得る(図9B)。比較すると、hAlb−hIL2およびhAlb−hIL2sの場合、抗原特異的T細胞の拡大は、おそらく誘導されたTregによるエフェクタT細胞の抑制に起因して、2回目の処置後に減速する(図9B、C)。同様に、CD8+T細胞数は、mutCD25およびmutβγ変異を含むhAlb−hIL2_A4sおよびhAlb−hIL2_A6s変異体によって最も強力に増加した(図9D)。結果として、抗原特異的T細胞対Treg比(図9E)およびCD8+T細胞対Treg比(図9F)は両方とも、hAlb−hIL2およびhAlb−hIL2sと比較して、hAlb−hIL2_A4sおよびhAlb−hIL2_A6s変異体の投与によって大幅に増加した。すべてのhAlb−hIL2変異体、特にhAlb−hIL2_A4sとhAlb−hIL2_A6sは、非特異的CD8+(テトラマー−/CD8+)T細胞と比較して抗原特異的T細胞(テトラマー+/CD8+)を選択的に拡大した(図9G)。興味深いことに、hAlb−hIL2_A4sおよびhAlb−hIL2_A6sは、hAlb−hIL2およびhAlb−hIL2sよりも低い頻度のKLRG1+CD127−短命エフェクタT細胞(SLEC)を誘導した(図9H)。SLECの高い頻度は、記憶形成の可能性の低下のために、T細胞応答の寿命にマイナスの影響を及ぼす(Joshi,N.S.et al.Immunity 27,281−295(2007))。さらに、hAlb−hIL2_A4sおよびhAlb−hIL2_A6s変異体は、hAlb−hIL2よりもはるかに強力に、およびhAlb−hIL2sよりもわずかに強力にNK細胞を拡大した(図9I)。mutβγ変異を含むすべての変異体は、hAlb−hIL2と比較して有意に高い割合のKLRG1発現NK細胞を生じさせ、エフェクタ表現型が活性化されていることを示した(図9J)。KLRG1陽性NK細胞は、肺転移性疾患から保護することが示された(Renner,P.et al.Oncoimmunology 3,e28328(2014))。活性化されたNK細胞の短命な性質のために、mutβγ変異を含むすべての変異体で最初の処置後にNK細胞数が減少するが、依然としてhAlb対照群より高いままである(図9I)。
hAlb−hIL2_A4sの投与はCD4+T細胞応答をブーストする
以前の実験で、本発明人は、mutCD25とmutβγの両方の変異を含むIL2変異体の投与が抗原特異的CD8+T細胞の誘導を増強することを明らかにした。CD4+T細胞がこれらのIL2変異体から恩恵を受けるかどうかをさらに試験するために、C57BL/6マウス(群あたりn=7)に、0日目、7日目および14日目に20μgのB16_M30(Kreiter,S.et al.Nature 520,692−696(2015))RNA−LPXおよび3μgのhAlb、hAlb−hIL2またはhAlb−hIL2_A4s RNA−LNPを静脈内投与した。フローサイトメトリによる血液リンパ球の分析(実施例8を参照)を19日目に実施した(図10A)。B16_M30は、CD4+T細胞によって認識されるB16F10腫瘍細胞株のMHCクラスII拘束性ネオエピトープである(Kreiter,S.et al.Nature 520,692−696(2015))。
mutCD25変異とmutβγ変異を組み合わせたIL2変異体は、癌ワクチン接種の抗腫瘍効果を増強する
ワクチン接種によって誘導される腫瘍抗原特異的T細胞は腫瘍増殖を制御することができ、一方TregはエフェクタT細胞の作用を阻害する(Kreiter,S.et al.Nature 520,692−696(2015))。本発明人は以前に、hAlb−hIL2がCT26腫瘍担持マウスにおけるgp70 RNAワクチン接種の抗腫瘍効果を有意に改善できることを示した。したがって、hAlb−hIL2_A4sおよびhAlb−hIL2_A6sなどのTregを増加させないhAlb−hIL2の改善された変異体は、治療上さらにより有効であると予想される。
Claims (52)
- ヒトインターロイキン−2(IL2)またはヒトIL2の機能的変異体のムテインを含むポリペプチドであって、前記ヒトIL2またはその機能的変異体が、αβγ IL2受容体複合体(IL2Rαβγ)のアルファサブユニットと接触する野生型ヒトIL2内の少なくとも酸性または塩基性アミノ酸残基を有する位置で置換されており、前記アミノ酸残基が野生型ヒトIL2内の酸性アミノ酸残基である場合、前記置換は塩基性アミノ酸残基によるものであり、および前記アミノ酸残基が野生型ヒトIL2内の塩基性アミノ酸残基である場合、前記置換は酸性アミノ酸残基によるものである、ポリペプチド。
- 野生型ヒトIL2が、配列番号17に従うアミノ酸配列を有する、請求項1に記載のポリペプチド。
- 野生型ヒトIL2内の前記酸性アミノ酸残基が、IL2Rαβγのアルファサブユニットの塩基性アミノ酸残基と接触する、請求項1または2に記載のポリペプチド。
- 野生型ヒトIL2内の前記塩基性アミノ酸残基が、IL2Rαβγのアルファサブユニットの酸性アミノ酸残基と接触する、請求項1〜3のいずれか一項に記載のポリペプチド。
- 前記置換がIL2Rαβγに対する親和性を低下させる、請求項1〜4のいずれか一項に記載のポリペプチド。
- 前記置換が、IL2Rαβγに対する親和性をβγ IL2受容体複合体(IL2Rβγ)に対する親和性よりも大幅に低下させる、請求項1〜5のいずれか一項に記載のポリペプチド。
- 前記ポリペプチドが、制御性T細胞よりもエフェクタT細胞を選択的に活性化する、請求項1〜6のいずれか一項に記載のポリペプチド。
- 前記ヒトIL2またはその機能的変異体が、野生型ヒトIL2と比較して、および野生型ヒトIL2に従って番号付けされた、35位(リジン)、43位(リジン)、61位(グルタミン酸)および62位(グルタミン酸)の少なくとも1つで置換されている、請求項1〜7のいずれか一項に記載のポリペプチド。
- 35位が置換されている、請求項8に記載のポリペプチド。
- 35位がグルタミン酸で置換されている、請求項8または9に記載のポリペプチド。
- 43位が置換されている、請求項8〜10のいずれか一項に記載のポリペプチド。
- 43位がグルタミン酸で置換されている、請求項8〜11のいずれか一項に記載のポリペプチド。
- 61位が置換されている、請求項8〜12のいずれか一項に記載のポリペプチド。
- 61位がリジンで置換されている、請求項8〜13のいずれか一項に記載のポリペプチド。
- 62位が置換されている、請求項8〜14のいずれか一項に記載のポリペプチド。
- 62位がリジンで置換されている、請求項8〜15のいずれか一項に記載のポリペプチド。
- 43位および61位が置換されている、請求項8〜16のいずれか一項に記載のポリペプチド。
- 43位がグルタミン酸で置換され、および61位がリジンで置換されている、請求項8〜17のいずれか一項に記載のポリペプチド。
- 35位、43位および61位が置換されている、請求項8〜18のいずれか一項に記載のポリペプチド。
- 35位がグルタミン酸で置換され、43位がグルタミン酸で置換され、および61位がリジンで置換されている、請求項8〜19のいずれか一項に記載のポリペプチド。
- 61位および62位が置換されている、請求項8〜20のいずれか一項に記載のポリペプチド。
- 61位がリジンで置換され、および62位がリジンで置換されている、請求項8〜21のいずれか一項に記載のポリペプチド。
- 前記ヒトIL2またはその機能的変異体が、IL2Rβγに対する親和性を増強する1つ以上のアミノ酸置換をさらに含む、請求項1〜22のいずれか一項に記載のポリペプチド。
- ヒトインターロイキン−2(IL2)またはヒトIL2の機能的変異体のムテインを含むポリペプチドであって、前記ヒトIL2またはその機能的変異体が、少なくとも(i)IL2Rαβγのアルファサブユニットに対する親和性を低下させる1つ以上のアミノ酸置換および(i)IL2Rβγに対する親和性を増強する1つ以上のアミノ酸置換を含む、ポリペプチド。
- IL2Rαβγのアルファサブユニットに対する親和性を低下させる前記1つ以上のアミノ酸置換が、K35、T37、R38、T41、F42、K43、F44、Y45、E61、E62、K64、P65、E68、L72、およびY107からなる群より選択されるIL2またはその機能的変異体の1つ以上の位置における置換を含む、請求項24に記載のポリペプチド。
- IL2Rβγに対する親和性を増強する前記1つ以上のアミノ酸置換が、K9、L12、Q13、E15、H16、D20、Q74、L80、R81、D84、L85、I86、N88、I92、L94、およびE95からなる群より選択されるIL2の1つ以上の位置における置換を含む、請求項23〜25のいずれか一項に記載のポリペプチド。
- IL2Rβγに対する親和性を増強する前記1つ以上のアミノ酸置換が、80F、81D、85V、86V、92Fの置換のセットを含む、請求項23〜26のいずれか一項に記載のポリペプチド。
- 前記IL2または前記置換されたIL2もしくはその機能的変異体に融合した前記IL2の機能的変異体に対して異種であるアミノ酸配列をさらに含む延長薬物動態(PK)IL2である、請求項1〜27のいずれか一項に記載のポリペプチド。
- 前記IL2またはその機能的変異体に対して異種であるアミノ酸配列が、血清アルブミン、免疫グロブリン断片、トランスフェリン、およびFn3、またはそれらの変異体からなる群より選択される、請求項28に記載のポリペプチド。
- 前記血清アルブミンがマウス血清アルブミンまたはヒト血清アルブミンを含む、請求項29に記載のポリペプチド。
- 前記免疫グロブリン断片が免疫グロブリンFcドメインを含む、請求項29に記載のポリペプチド。
- 請求項1〜31のいずれか一項に記載のポリペプチドをコードするポリヌクレオチド。
- RNAである、請求項32に記載のポリヌクレオチド。
- 請求項32または33に記載のポリヌクレオチドを含む宿主細胞。
- 請求項1〜31のいずれか一項に記載のポリペプチド、請求項32もしくは33に記載のポリヌクレオチド、または請求項34に記載の宿主細胞を含む医薬組成物。
- 請求項1〜31のいずれか一項に記載のポリペプチド、請求項32もしくは33に記載のポリヌクレオチド、請求項34に記載の宿主細胞、または請求項35に記載の医薬組成物を対象に投与することを含む、前記対象を治療する方法。
- 前記対象が癌を有する、請求項36に記載の方法。
- 対象において免疫応答を誘導するための方法であって、前記対象に、
a.請求項1〜31のいずれか一項に記載のポリペプチド、請求項32もしくは33に記載のポリヌクレオチド、請求項34に記載の宿主細胞、または請求項35に記載の医薬組成物;および
b.前記対象において抗原に対する免疫応答を誘導するためのエピトープを含むペプチドまたはポリペプチド、または前記ペプチドもしくはポリペプチドをコードするポリヌクレオチド
を投与することを含む方法。 - 前記ペプチドまたはポリペプチドをコードする前記ポリヌクレオチドがRNAである、請求項38に記載の方法。
- 前記治療が制御性T細胞よりもエフェクタT細胞を活性化する、請求項36〜39のいずれか一項に記載の方法。
- 前記抗原が腫瘍関連抗原である、対象における癌を治療または予防するための方法である、請求項36〜40のいずれか一項に記載の方法。
- 対象における癌を治療または予防するための方法であって、前記対象に、
a.請求項1〜31のいずれか一項に記載のポリペプチド、請求項32もしくは33に記載のポリヌクレオチド、請求項34に記載の宿主細胞、または請求項35に記載の医薬組成物;および
b.前記対象において腫瘍関連抗原に対する免疫応答を誘導するためのエピトープを含むペプチドまたはポリペプチド、または前記ペプチドもしくはポリペプチドをコードするポリヌクレオチド
を投与することを含む方法。 - 前記癌が、黒色腫、白血病、リンパ腫、肺癌、乳癌、前立腺癌、卵巣癌、結腸癌、中皮腫、腎細胞癌、および脳の癌からなる群より選択される、請求項37、および40〜42のいずれか一項に記載の方法。
- a.請求項1〜31のいずれか一項に記載のポリペプチド、請求項32もしくは33に記載のポリヌクレオチド、請求項34に記載の宿主細胞、または請求項35に記載の医薬組成物
を含む医薬製剤。 - b.対象において抗原に対する免疫応答を誘導するためのエピトープを含むペプチドまたはポリペプチド、または前記ペプチドもしくはポリペプチドをコードするポリヌクレオチド
をさらに含む、請求項44に記載の医薬製剤。 - 各成分aおよびbを別々の容器内に含む、請求項45に記載の医薬製剤。
- 医薬組成物である、請求項44または45に記載の医薬製剤。
- 前記抗原が腫瘍関連抗原である、癌を治療または予防するための前記医薬製剤の使用説明書をさらに含む、請求項44〜46のいずれか一項に記載の医薬製剤。
- 医薬用途のための、請求項44〜48のいずれか一項に記載の医薬製剤。
- 前記医薬用途が、疾患または障害の治療的または予防的治療を含む、請求項49に記載の医薬製剤。
- 前記抗原が腫瘍関連抗原である、対象における癌を治療または予防するための方法で使用するための、請求項44〜48のいずれか一項に記載の医薬製剤。
- 前記癌が、黒色腫、白血病、リンパ腫、肺癌、乳癌、前立腺癌、卵巣癌、結腸癌、中皮腫、腎細胞癌、および脳の癌からなる群より選択される、請求項48〜51のいずれか一項に記載の医薬製剤。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP2018070068 | 2018-07-24 | ||
EPPCT/EP2018/070068 | 2018-07-24 | ||
PCT/EP2019/069541 WO2020020783A1 (en) | 2018-07-24 | 2019-07-19 | Il2 agonists |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2021531013A true JP2021531013A (ja) | 2021-11-18 |
Family
ID=67439198
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021503723A Pending JP2021531013A (ja) | 2018-07-24 | 2019-07-19 | Il2アゴニスト |
Country Status (12)
Country | Link |
---|---|
US (1) | US20210292386A1 (ja) |
EP (1) | EP3827014A1 (ja) |
JP (1) | JP2021531013A (ja) |
KR (1) | KR20210038549A (ja) |
CN (1) | CN112771072A (ja) |
AU (1) | AU2019311233A1 (ja) |
BR (1) | BR112021000811A8 (ja) |
CA (1) | CA3106858A1 (ja) |
IL (1) | IL280290A (ja) |
MX (1) | MX2021000801A (ja) |
SG (1) | SG11202013044PA (ja) |
WO (1) | WO2020020783A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2022500002A (ja) * | 2018-09-21 | 2022-01-04 | イノベント バイオロジックス (スウツォウ) カンパニー,リミテッド | 新規インターロイキン2およびその使用 |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3056630A1 (en) | 2017-03-15 | 2018-09-20 | Pandion Therapeutics, Inc. | Targeted immunotolerance |
CA3064435A1 (en) | 2017-05-24 | 2018-11-29 | Pandion Therapeutics, Inc. | Targeted immunotolerance |
US20200181220A1 (en) | 2017-08-03 | 2020-06-11 | Synthorx, Inc. | Cytokine conjugates for the treatment of proliferative and infectious diseases |
US10174091B1 (en) | 2017-12-06 | 2019-01-08 | Pandion Therapeutics, Inc. | IL-2 muteins |
US10946068B2 (en) | 2017-12-06 | 2021-03-16 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
KR20210143759A (ko) * | 2019-03-18 | 2021-11-29 | 비온테크 쎌 & 제네 테라피스 게엠베하 | 면역 작용 세포의 특이적 활성화를 위한 인터루킨-2 수용체 (il2r) 및 인터루킨-2 (il2) 변이체 |
BR112021023345A2 (pt) | 2019-05-20 | 2022-02-01 | Pandion Operations Inc | Imunotolerância com alvo em madcam |
TW202115105A (zh) * | 2019-06-24 | 2021-04-16 | 德商拜恩迪克Rna製藥有限公司 | Il2激動劑 |
MX2022007754A (es) | 2019-12-20 | 2022-07-19 | Regeneron Pharma | Nuevos agonistas de il2 y metodos de uso de estos. |
EP4122951A1 (en) * | 2020-03-19 | 2023-01-25 | Innovent Biologics (Suzhou) Co., Ltd. | Interleukin-2 mutant and use thereof |
AR121713A1 (es) | 2020-03-31 | 2022-06-29 | Hanmi Pharm Ind Co Ltd | Nuevos análogos de il-2 inmunoestimulantes |
CA3168737A1 (en) | 2020-04-21 | 2021-10-28 | Jiaxi WU | Il-2 variants with reduced binding to il-2 receptor alpha and uses thereof |
EP4161956A1 (en) | 2020-06-03 | 2023-04-12 | Ascendis Pharma Oncology Division A/S | Il-2 sequences and uses thereof |
JPWO2022059794A1 (ja) * | 2020-09-18 | 2022-03-24 | ||
WO2023131270A1 (en) * | 2022-01-07 | 2023-07-13 | Cure Genetics, Co., Limited | Novel interleukin-2 polypeptides |
WO2023137346A2 (en) * | 2022-01-11 | 2023-07-20 | Outpace Bio, Inc. | Designed cytokine compositions and methods of use |
WO2023180527A1 (en) | 2022-03-25 | 2023-09-28 | Universität Zürich | Adenoviral mediated targeting of activated immune cells |
WO2024002363A1 (en) * | 2022-07-01 | 2024-01-04 | Beijing Neox Biotech Limited | Il-2 polypeptides and methods of use |
CN117903283A (zh) * | 2022-10-19 | 2024-04-19 | 北京志道生物科技有限公司 | 一种il-2突变体 |
CN116041539B (zh) * | 2022-10-31 | 2023-07-21 | 山东博安生物技术股份有限公司 | Il-2突变体免疫缀合物 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018091003A1 (es) * | 2016-11-15 | 2018-05-24 | Centro De Inmunología Molecular | Método para incrementar los niveles de secreción de la interleucina 2 y sus proteínas derivadas |
Family Cites Families (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2686899B1 (fr) | 1992-01-31 | 1995-09-01 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant. |
DZ2788A1 (fr) * | 1998-05-15 | 2003-12-01 | Bayer Ag | Agonistes et antagonistes selectifs à IL-2. |
US20050287153A1 (en) | 2002-06-28 | 2005-12-29 | Genentech, Inc. | Serum albumin binding peptides for tumor targeting |
US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
US7176278B2 (en) | 2001-08-30 | 2007-02-13 | Biorexis Technology, Inc. | Modified transferrin fusion proteins |
US7696320B2 (en) | 2004-08-24 | 2010-04-13 | Domantis Limited | Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor |
AU2003263552A1 (en) * | 2002-09-09 | 2004-03-29 | Nautilus Biotech | Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules |
ES2655912T3 (es) | 2002-11-08 | 2018-02-22 | Ablynx N.V. | Anticuerpos de dominio simple dirigidos contra factor de necrosis tumoral-alfa y usos para los mismos |
WO2005007121A2 (en) * | 2003-07-18 | 2005-01-27 | Massachusetts Institute Of Technology | Mutant interleukin-2(il-2) polypeptides |
MXPA06009072A (es) | 2004-02-09 | 2007-03-29 | Human Genome Sciences Inc | Proteinas de fusion de albumina. |
CN1930300A (zh) * | 2004-03-05 | 2007-03-14 | 希龙公司 | 预测患者治疗药物耐受性的体外试验系统 |
RU2006135112A (ru) * | 2004-03-05 | 2008-04-10 | Чирон Корпорейшн (Us) | Тест-система in vitro для прогнозирования устойчивости пациента к терапевтическим средствам |
US20070269422A1 (en) | 2006-05-17 | 2007-11-22 | Ablynx N.V. | Serum albumin binding proteins with long half-lives |
EP2046826B1 (en) | 2006-07-24 | 2011-09-14 | Biorexis Pharmaceutical Corporation | Exendin fusion proteins |
JP2010502208A (ja) | 2006-09-08 | 2010-01-28 | アブリンクス エン.ヴェー. | 半減期の長い血清アルブミン結合タンパク質 |
CA2583716A1 (en) * | 2007-04-18 | 2008-10-18 | Nautilus Biotech | Oral dosage formulations of protease resistant polypeptides |
WO2009061853A2 (en) * | 2007-11-05 | 2009-05-14 | Massachusetts Institute Of Technology | Mutant interleukin-2 (il-2) polypeptides |
US20100322930A1 (en) | 2007-12-27 | 2010-12-23 | Frank Kolbinger | Fibronectin-based binding molecules and their use |
WO2009133208A1 (en) | 2008-05-02 | 2009-11-05 | Novartis Ag | Improved fibronectin-based binding molecules and uses thereof |
CA2779073C (en) | 2009-10-30 | 2017-10-24 | Domain Therapeutics | Novel oxime derivatives and their use as allosteric modulators of metabotropic glutamate receptors |
US10233228B2 (en) | 2010-04-09 | 2019-03-19 | Albumedix Ltd | Albumin derivatives and variants |
DK2558491T3 (en) | 2010-04-13 | 2018-10-15 | Bristol Myers Squibb Co | Fibronectin-based Scaffold domain proteins that bind PCSK9 |
CN102101885B (zh) * | 2010-09-01 | 2013-06-05 | 南京发士达生物科技有限公司 | 低诱导抑制性t细胞的人白细胞介素ⅱ突变体及其用途 |
US9428567B2 (en) * | 2010-12-22 | 2016-08-30 | The Board Of Trustees Of The Leland Stanford Junior University | Antagonists of interleukin-2 receptor |
DK3489255T3 (da) * | 2011-02-10 | 2021-08-23 | Roche Glycart Ag | Muterede interleukin-2-polypeptider |
WO2012119093A1 (en) * | 2011-03-03 | 2012-09-07 | Board Of Trustees Of The Leland Stanford Junior University | Superagonists and antagonists of interleukin-2 |
EP2780364A2 (en) | 2011-11-18 | 2014-09-24 | Eleven Biotherapeutics, Inc. | Proteins with improved half-life and other properties |
WO2013143555A1 (en) | 2012-03-26 | 2013-10-03 | Biontech Ag | Rna formulation for immunotherapy |
AU2014232416B2 (en) * | 2013-03-15 | 2017-09-28 | Xencor, Inc. | Modulation of T Cells with Bispecific Antibodies and FC Fusions |
CA2946398A1 (en) * | 2014-04-24 | 2015-10-29 | The Board Of Trustees Of The Leland Stanford Junior University | Superagonists, partial agonists and antagonists of interleukin-2 |
WO2017059902A1 (en) | 2015-10-07 | 2017-04-13 | Biontech Rna Pharmaceuticals Gmbh | 3' utr sequences for stabilization of rna |
-
2019
- 2019-07-19 CA CA3106858A patent/CA3106858A1/en active Pending
- 2019-07-19 BR BR112021000811A patent/BR112021000811A8/pt unknown
- 2019-07-19 WO PCT/EP2019/069541 patent/WO2020020783A1/en unknown
- 2019-07-19 AU AU2019311233A patent/AU2019311233A1/en active Pending
- 2019-07-19 JP JP2021503723A patent/JP2021531013A/ja active Pending
- 2019-07-19 CN CN201980049332.XA patent/CN112771072A/zh active Pending
- 2019-07-19 SG SG11202013044PA patent/SG11202013044PA/en unknown
- 2019-07-19 KR KR1020217002155A patent/KR20210038549A/ko unknown
- 2019-07-19 MX MX2021000801A patent/MX2021000801A/es unknown
- 2019-07-19 US US17/262,097 patent/US20210292386A1/en active Pending
- 2019-07-19 EP EP19744656.0A patent/EP3827014A1/en active Pending
-
2021
- 2021-01-19 IL IL280290A patent/IL280290A/en unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018091003A1 (es) * | 2016-11-15 | 2018-05-24 | Centro De Inmunología Molecular | Método para incrementar los niveles de secreción de la interleucina 2 y sus proteínas derivadas |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2022500002A (ja) * | 2018-09-21 | 2022-01-04 | イノベント バイオロジックス (スウツォウ) カンパニー,リミテッド | 新規インターロイキン2およびその使用 |
Also Published As
Publication number | Publication date |
---|---|
WO2020020783A1 (en) | 2020-01-30 |
SG11202013044PA (en) | 2021-02-25 |
EP3827014A1 (en) | 2021-06-02 |
BR112021000811A8 (pt) | 2022-10-18 |
CN112771072A (zh) | 2021-05-07 |
CA3106858A1 (en) | 2020-01-30 |
MX2021000801A (es) | 2021-04-12 |
IL280290A (en) | 2021-03-01 |
BR112021000811A2 (pt) | 2021-04-13 |
AU2019311233A1 (en) | 2021-01-21 |
US20210292386A1 (en) | 2021-09-23 |
KR20210038549A (ko) | 2021-04-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2021531013A (ja) | Il2アゴニスト | |
JP2021513570A (ja) | サイトカインをコードするrnaを用いた治療 | |
US20220356223A1 (en) | IL2 Agonists | |
US20220143144A1 (en) | Treatment involving interleukin-2 (il2) and interferon (ifn) | |
JP2023508653A (ja) | 抗原受容体を発現するように遺伝子的に改変された免疫エフェクター細胞を伴う処置 | |
US20220177544A1 (en) | Interleukin-2 receptor (IL2R) and interleukin-2 (IL2) variants for specific activation of immune effector cells | |
JP2022519713A (ja) | Car操作されたt細胞およびサイトカインを含む治療 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A712 Effective date: 20220207 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220414 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20230329 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230404 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20230630 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20230904 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20231002 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20231219 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240419 |